Review Article

Estrogen Signaling in Metabolic Inflammation

Rosário Monteiro,1 Diana Teixeira,1 and Conceição Calhau1,2

1 Department of Biochemistry, Faculty of Medicine, University of Porto, Medical Investigation Center, 4200-319 Porto, Portugal
2 Center for Research in Health Technologies and Information Systems (CINTESIS), 4200-450 Porto, Portugal

Correspondence should be addressed to Rosário Monteiro; rosariom@med.up.pt

Received 15 July 2014; Accepted 7 October 2014; Published 23 October 2014

Academic Editor: Dmitri V. Krysko

Copyright © 2014 Rosário Monteiro et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

There is extensive evidence supporting the interference of inflammatory activation with metabolism. Obesity, mainly visceral obesity, is associated with a low-grade inflammatory state, triggered by metabolic surplus where specialized metabolic cells such as adipocytes activate cellular stress initiating and sustaining the inflammatory program. The increasing prevalence of obesity, resulting in increased cardiometabolic risk and precipitating illness such as cardiovascular disease, type 2 diabetes, fatty liver, cirrhosis, and certain types of cancer, constitutes a good example of this association. The metabolic actions of estrogens have been studied extensively and there is also accumulating evidence that estrogens influence immune processes. However, the connection between these two fields of estrogen actions has been underacknowledged since little attention has been drawn towards the possible action of estrogens on the modulation of metabolism through their anti-inflammatory properties. In the present paper, we summarize knowledge on the modification inflammatory processes by estrogens with impact on metabolism and highlight major research questions on the field. Understanding the regulation of metabolic inflammation by estrogens may provide the basis for the development of therapeutic strategies to the management of metabolic dysfunctions.

1. Introduction

The epidemic increase in obesity has been paralleled by the rise in cardiovascular disease, type 2 diabetes, fatty liver, cirrhosis, asthma, neurodegenerative diseases, and certain types of cancer [1, 2] and subsequently linked to reduced life expectancy and premature death [3].

The finding that obesity is associated with a systemic low-grade subacute inflammatory state and that inflammation mediates many of the pathological consequences of obesity has opened the avenue to the study of the interactions between metabolic and immunological processes [2]. After the acknowledgment of the adipose tissue (AT) as a true endocrine organ secreting hormones, cytokines, chemokines, and growth factors with influence on metabolism, vascular function, appetite and satiety, and fertility, among many others, came its recognition as a fundamental player in innate and acquired immune processes [4]. AT dysfunction has been considered a central component of obesity-related inflammation and the main instigator of the pathological consequences of obesity, much through its association with insulin resistance [5–7]. However, the AT is not the only source of inflammatory mediators in obesity, since the liver, the pancreas, and the muscle do also contribute to inflammation and are affected by it [3].

In addition, it is well established that the performance of immune cells is largely influenced by metabolic cues and both metabolic and immune systems are highly interdependent [1]. These systems have evolved in close relationship, sharing cellular machinery, being activated by many common hormones, cytokines, signaling proteins, transcription factors, and bioactive lipids and regulating each other. The inflammatory response relies on energetic support from the metabolic system, favoring a catabolic state and suppressing anabolic processes such as those initiated by insulin [8].

Estrogens influence immune and inflammatory processes, as revealed by increased inflammatory responses to infection and sepsis and higher rate of autoimmune diseases in women when compared to men as well as by the variation of chronic inflammatory disease activity with the menstrual cycle, pregnancy, and menopause [9, 10]. Likewise, models of estrogen insufficiency have unveiled new and unexpected
roles for estrogens, in both males and females, many of which apply to the regulation of energy homeostasis [11, 12]. However, these two lines of research have been mostly independent and little attention has been drawn towards the possible action of estrogens on the modulation of metabolism through their anti-inflammatory properties. This is a subject of undisputable interest since understanding the regulation of metabolic inflammation by estrogens has the potential of providing new therapies to this increasingly prevalent condition.

In this paper, we will synthesize the current knowledge on how estrogen signaling may modify inflammatory processes thus impacting on metabolism and highlight major research questions on the field.

2. Metabolic Inflammation

Inflammation involves the coordinated action of many cell types and mediators in response to harmful stimuli (e.g., physical, chemical, or biological), resulting in neutralization or removal of the insult usually leading to the restoration of homeostasis [13]. It has been highlighted that obesity-associated inflammation does not meet the criteria of classical inflammation, presenting in a peculiar way, not accompanied by infection or signs of autoimmunity, and without extensive tissue injury [1]. Instead, inflammatory activation is often modest and local as compared with that elicited by infection, trauma, or acute immune response [3], being mainly triggered by metabolic surplus [1] with specialized metabolic cells such as adipocytes [3] activating cellular stress pathways [14], thus initiating and sustaining the inflammatory program [3]. It may be understood as a failure to completely restore prior homeostasis, reaching a new equilibrium status (allostasis), with permanently modulated functions [14]. Different proposals have been made to name this inflammatory state as “metaflammation,” meaning metabolically triggered inflammation [1], or “para-inflammation,” defining an intermediate condition between basal and inflammatory states [15]. This has defined the field of immunometabolism as the framework for the occurrence of many metabolic diseases [2, 7]. However, the comprehensiveness of the inflammatory process, as it deals with coagulation, fibrinolysis, complement activation, antioxidation, immune response, and regulation of hormones by the hypothalamic-pituitary-adrenal axis complicates the study of metabolic inflammation. Likewise, in addition to genetic and environmental influences, the possible wide range of mass variability of the tissue most contributing to inflammation, in this case, the AT, makes the subject even more intricate [16].

2.1. Initiating Factors and Mechanisms. Under conditions of overfeeding or high fat diets, specialized metabolic cells (e.g., adipocytes, hepatocytes, or myocytes) may engage in cell defensive programs initiating inflammatory activation and communication in response to danger signals. These inflammatory pathways include inflammasome and pattern recognition receptors such as the toll-like receptor (TLR) activation, c-jun N-terminal kinase (JNK), inhibitor of kappaB kinase (IKK)/nuclear factor kappa B (NFkappaB), peroxisome proliferator-activated receptor (PPAR) gamma signaling, and production of inflammatory cytokines [3]. Many of these responses are mediated by disturbances of organelle functioning such as the endoplasmic reticulum or the mitochondria [17, 18]. Affected cells secrete increased amounts of inflammatory cytokines and decreased protective factors (e.g., adiponectin) and the systemic nature of the response is revealed by the increase in circulating acute-phase reactants (e.g., C-reactive protein, CRP) [7, 19]. Increased release of chemotactic molecules mediates the recruitment of immune cells such as macrophages, mast cells, lymphocytes, eosinophils, and dendritic cells to inflamed tissues [20]. The importance of immune cell infiltration in the AT has been extensively studied and seems to largely contribute to obesity-related metabolic dysfunction and chronic inflammation [21]. Interestingly, over 90% of the cytokines released by AT, with the exception of adiponectin and leptin, can be attributed to cells other than adipocytes [22].

Several possible initiating signals have been proposed for the origin of metabolic inflammation signaling, for example: (i) nutrients may be naturally inflammatory [3]; (ii) increased intestinal permeability after fatty meals or in obese states may allow access of proinflammatory stimuli such as lipopolysaccharide (LPS) to the circulation [23, 24]; (iii) nutrients, not being inflammatory by nature, when in excess initiate immune responses due to a dose-dependent loss of specificity (e.g., excess lipids activating TLRs) [3]. Besides, LPS and nonesterified fatty acids, glucose, hypoxia, cell damage, and death can activate metabolic inflammation in various cells types [6, 8, 25–28]. The repetitive or chronic presence of such stimuli, even of moderate magnitude, either isolated or in combination, disrupts homeostasis creating vicious cycles that reinforce each other [29].

3. Estrogens

Estrogens have well-established roles in reproductive function, but their effects on other systems have been brought to light, namely, in adipose, nervous, cardiovascular, muscle, and bone tissues, implicating these hormones in many diverse physiological roles.

3.1. Estrogen Metabolism. Estrogens are synthesized by aromatase, a cytochrome P450 enzyme located in the endoplasmic reticulum of estrogen producing cells which catalyzes the aromatization of testosterone and androstenedione [30], to 17beta-estradiol, the most active estrogen, and estrone, respectively [31]. In humans, estrogens are generated in several tissues including the ovaries, testis, placenta, fetal but not adult liver, bone chondrocytes and osteoblasts, vascular smooth muscle cells, skin, skeletal muscle, several brain regions, and the AT [30, 32, 33]. The gonads and the adrenals express all the necessary enzymes to synthesize estrogens from cholesterol whereas other tissues, such as the bone or the AT, depend on precursor supply from those organs through the blood [34]. In peripheral tissues, 17beta-hydroxysteroid dehydrogenase (17beta-HSD) converts the weaker hormones
androstenedione and estrone to stronger ones, testosterone and 17beta-estradiol, respectively (Figure 1) [35, 36].

In premenopausal women, most estrogens are produced in the ovaries, released to the circulation in large amounts and exert their effects in many target tissues through endocrine signaling. After menopause, when estrogen production from the ovaries falls, circulating levels of estrogens decrease dramatically [37] and estrogen synthesis is mainly assured by peripheral sources, primarily by the AT [38]. The AT can contribute with around 100% of circulating estrogens in postmenopausal women [39, 40]. Estrogens are also produced during the entire male life cycle, having an action pattern similar to that of postmenopausal women in which endocrine actions lose relevance to paracrine, autocrine, and intracrine actions in the tissues or in the cells that produce them [30]. Thus, regardless of low circulating levels, local estrogen concentrations may be high, reflecting on their biological actions [41].

Estrogen inactivation occurs via estrogen sulfotransferase which constitutes a critical mediator of hormone action. This cytosolic enzyme conjugates estrogens with sulfate, inactivating them and favoring urinary excretion [12]. Although estrogen sulfates are biologically inactive, they have prolonged half-life in the circulation, acting as a reservoir for regeneration of active estrogens by steroid sulfatase-mediated desulfation [42].

3.2. Estrogen Signaling. Estrogen signaling occurs through both genomic and nongenomic mechanisms summarized in Figure 2. Classical, genomic, estrogen signaling has been described to occur through specific nuclear receptors acting as ligand-activated transcription factors [12, 43], the estrogen receptors (ERs), of which two isomers are known: ERalpha and ERbeta [9, 44, 45]. ER distribution varies among tissues resulting in distinct effects of the hormone in different locations and the relative amount of each subtype may also
change estrogen effects [9]. ERalpha is the predominant receptor in the kidney [43], heart [46], bone, uterus, liver, and AT [47], whereas ERbeta is the predominant receptor in the ovary, prostate, lung, bladder, hematopoietic cells, gastrointestinal tract, and central nervous system [43, 47]. Classical genomic signaling through the ER occurs within hours of ligand binding, activating or repressing target genes. ERs are located as monomers in the cytoplasm in protein complexes involving chaperone heat-shock proteins and estrogen binding promotes their dissociation from this complex and ER dimerization. ER dimers bind directly to estrogen response elements of target gene promoters, or indirectly through interaction with other DNA-bound transcription factors. ERs also regulate gene expression in a ligand independent manner being activated downstream to growth factors binding to growth factor receptors, through the action of intracellular kinases or through the formation of heterodimers with different nuclear receptors (not shown). Genomic actions are modulated by cell-specific interaction with cofactors (coactivators or cosuppressors).

Metabolic effects of estrogens seem to be largely mediated through nonnuclear ERs, either by interference with gene expression or by exerting nongenomic actions. This involves activation of ERs and G-protein-coupled ER located at the membrane or at extranuclear sites within seconds or minutes resulting in changes in Ca\(^{2+}\), K\(^{+}\), cAMP, and nitric oxide levels, activation of G protein-mediated events, and stimulation of different types of kinases such as extracellular-regulated kinases, phosphoinositide 3-kinases, mitogen-activated protein kinase, and c-Jun N-terminal kinases. E: estrogen; ER: estrogen receptor; ERE: estrogen-responsive element; ERK: extracellular-regulated kinase; GFR: growth factor receptor; GPER: G protein-coupled estrogen receptor; HSP: heat-shock protein; JNK: c-Jun N-terminal kinase; MAPK: mitogen-activated protein kinase; NO: nitric oxide; PI3K: phosphoinositide-3 kinase; TF: transcription factor.

While most of the reproductive effects of estrogens are mediated through classical ER signaling, metabolic effects seem to be largely mediated through nonnuclear ERs, either by interference with gene expression or by exerting nongenomic actions. This involves activation of ERs located at the membrane or at extranuclear sites within seconds or minutes [12, 50]. Mechanisms of nongenomic actions are not completely known but second messenger activation after estrogen binding results in changes in Ca\(^{2+}\), K\(^{+}\), CAMP,
and nitric oxide levels, activation of G protein-mediated events, and stimulation of different types of kinases such as extracellular-regulated kinases (Ras/Raf/MEK/ERK), phosphoinositide 3-kinases (PI3K), p38 mitogen-activated protein kinase (MAPK), and JNK [51–53]. MEK/ERK pathway activation also regulates gene expression through activation of transcriptional factors such as cAMP-related element binding (CREB) protein or nuclear factor of activated T-cells [54].

G protein-coupled receptor 30, now known as G-protein-coupled ER (GPER), located on the plasma membrane [55] or with an intracellular localization [56] is involved in rapid nongenomic estrogen signaling involving release of intracellular Ca\textsuperscript{2+} and activation of calcium-calmodulin-dependent kinases, PI3K and MAPKs [43].

Estrogen-related receptors (ERRs), a family of orphan receptors closely related to ERs, include three members, ERRalpha, ERRbeta, and ERRgamma, and are expressed in muscle, heart, bone, and AT [57]. These nuclear receptors are not stimulated by estrogens or estrogen-like molecules, being constitutively active in the absence of ligand [58]. However, ERRs can interfere with estrogen signaling, recognizing the same DNA-binding elements as ERs and sharing common target genes [57]. ER and ERR are coexpressed in many tissues and ERRs play important functions in adaptive energy metabolism [58].

With much relevance to the inflammation modulatory properties of estrogens is their capacity to influence NFκB activity through genomic and nongenomic mechanisms. NFκB is a central regulator of a variety of proinflammatory genes. It represents a homo- or heterodimeric complex of the REL family of proteins comprising p65 (Rel A), p50/105, p52/100, and Rel B. In its inactive form in unstimulated cells, NFκB resides in the cytoplasm bound to IkB. Upon stimulation achieved by different stimuli such as oxidative stress, viruses, and cytokines, IkB is phosphorylated mainly by IKK leading to IkB/NFκB complex dissociation and IkB ubiquitination followed by proteasome-mediated degradation. This allows formation of NFκB dimers (heterodimer formation is necessary for transcriptional activation) that translocate to the nucleus, bind to κB sites on target genes, and modulate expression of genes involved on inflammatory pathways and protective cellular responses. However, sustained NFκB activation can lead to chronic inflammation [46, 59, 60].

Estrogens may interfere with NFκB signaling by multiple mechanisms. ERs can bind to c-Rel and RelA in a ligand-independent manner interfering with the formation of active NFκB dimers [61–63]. Additionally, the atherogenic diet-induced in vivo hepatic NFκB activation was blocked by estrogen replacement in an ER-dependent manner [64]. Estrogens also indirectly inhibit NFκB DNA binding, as they have been shown to inhibit IKK activation, increase IkB expression, and decrease its phosphorylation [60, 65–68]. Furthermore 17beta-estradiol, membrane impermeable 17beta-estradiol, and overexpression of ERalpha may inhibit inflammatory activation mediated by NFκB and JNK via PI3K/AKT [69]. However, effects obtained vary according to cell type, relative abundance of the different ER subtypes, and timing at which effects are observed following estrogen exposure [46].

4. Estrogen Signaling in Metabolic Inflammation

Given the close interplay between both processes, it is impossible to approach the effects of estrogens on inflammation without having in mind that they exert a profound impact on metabolic regulation, the reverse also being true. However, in the past, most research has dealt with these two matters independently and only recently the modulation of metabolic dysfunction through changes in inflammation by estrogens is beginning to be unraveled. Even so, this kind of association has been more frequently established in regard to cancer, osteoporosis, cardiovascular disease, neurodegeneration, and stroke [70–74], still leaving many questions blank concerning obesity and insulin resistance. AT dysfunction has been considered a key initiating factor and the main source of inflammatory signaling in obesity-associated metabolic alterations, along with the resulting insulin resistant state [17, 75]. These two processes will therefore be the main scope of this review regarding their modulation by estrogen signaling, underscoring inflammatory mediators.

4.1. Energy Balance. Estrogens influence energy balance being usually regarded as opposing excessive body fat accumulation [76]. Multiple mechanisms account for this activity including actions on the central nervous system to regulate food intake and energy expenditure [77, 78] and direct effects on the physiology of the main energy metabolism-regulating organs such as the AT, the muscle, the liver, and the pancreas, where they regulate lipid and glucose metabolism, and also on immune cells [11, 12].

Estrogens decrease food intake and favor energy expenditure [78]. Ovariectomy leads to increased adiposity, partially by increasing food intake, which is prevented by estrogen treatment. In the same line, aromatase inactivation results in obesity without increasing food intake. Instead, aromatase knockout mice from both sexes show a decrease in spontaneous physical activity and decreased lean mass. ERalpha deficiency also increases food intake and decreases energy expenditure revealing the involvement of this ER subtype in energy balance regulation [12, 50].

4.2. Estrogens and Leptin. The regulation of leptin signaling by estrogens has been documented and may contribute to estrogens' effects on energy balance. Leptin receptor on the hypothalamus colocalizes with ERalpha and estrogen treatment decreases the expression of leptin receptor on the arcuate nucleus, where leptin exerts its catabolic actions being anorexigenic and increasing energy expenditure. Leptin is produced by adipocytes and the subcutaneous AT contributes most to leptin secretion due to higher mass (subcutaneous fat is the major fat storage depot in men and women) and higher expression in this location [79]. Leptin expression is highly influenced by estrogens [80], which are also produced in
higher amounts in subcutaneous AT [81]. In addition, estrogen treatment has been shown to increase leptin sensitivity in the brain both in males and in females while ovariectomy in females reduces it. Multiple factors, including inflammation and endoplasmic reticulum stress, have been shown to induce leptin resistance [82]. Furthermore, apart from its metabolic roles, leptin is an important mediator of immune responses and inflammation. Besides having direct roles in immune cells and inflammatory reactions [83, 84], leptin also influences inflammatory processes by mediating trade-offs between the immune system and other physiological systems to balance allocation of energy to inflammatory processes [85]. Therefore, the interaction between estrogens and leptin constitutes a possible indirect link between metabolic and inflammatory pathways.

4.3. Estrogens and Glucocorticoids. Estrogens’ influence on the hypothalamus-pituitary-adrenal-axis is another interesting hypothesis on how estrogens may impact on metabolic inflammation. Excess glucocorticoid signaling has been implicated in the development of visceral obesity and insulin resistance [86]. It has been proposed that glucocorticoid levels are elevated to counter inflammation in obesity and metabolic dysfunction resulting in insulin resistance, altered lipid metabolism, favored fat deposition, and protein mobilization. Estrogens may limit these actions of glucocorticoids and the inflammatory stimuli that lead to their elevation and fluctuations in estrogen levels during the life cycle can determine susceptibility to metabolic disorders [87, 88].

Estrogens are able to regulate the hypothalamus-pituitary-adrenal-axis through intrahypothalamic effects in the basal state and during restraint stress, an effect mediated by ERalpha and by both ERalpha and -beta, respectively [89]. Furthermore, the oleoyl ester of estrone, the storage from the AT of estrone, the main estrogen synthesized in this tissue from circulating androstenedione, regulates adrenal synthesis of corticosteroids. Oleoyl-estrone increased adrenal tissue corticosterone levels and gene expression of glucocorticoid-synthesizing enzymes reflecting higher serum corticosterone, while also increasing liver expression of corticosteroid-disposing steroid 5alpha-reductase, suggesting an increase in glucocorticoid turnover [90]. However, estrogens may also act by regulating glucocorticoid metabolism in peripheral tissues due to their ability to modulate 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1), the enzyme that activates circulating cortisol to cortisol (or 11-dehydrocorticosterone to corticosterone in rats), regulating glucocorticoid availability in a tissue-specific manner at the prereceptor level [91]. This enzyme modulates endogenous glucocorticoid action: acute inflammation is more evident in 11beta-HSD1 deficiency or inhibition. However, in obesity or diabetes, two chronic inflammatory conditions, reduced 11beta-HSD1 activity may be beneficial, contributing to decreased inflammation [92]. Estradiol treatment to ovariectomized rats downregulated liver and visceral, but not subcutaneous, AT 11beta-HSD1 activity and expression. This resulted in an alteration of the ratio of 11beta-HSD1 expression and activity between subcutaneous and visceral AT where estradiol-treated rats displayed increased subcutaneous compared to visceral 11betaHSD1, contrary to what was observed in untreated ovariectomized rats [93]. Using 3T3-L1 cells and adipocytes isolated from mesenteric fat depots, it has been shown that 17beta-estradiol treatment reduces 11beta-HSD1 expression within 5–10 minutes of stimulation without interference of ERs [94].

These actions are very relevant because, by decreasing glucocorticoid availability, estrogens oppose to their effects on the promotion of metabolic disturbances. On the liver, chronic 17beta-estradiol administration resulted in substantial inhibition of 11betaHSD1 mRNA expression and enzyme activity. Inhibition of 11beta-HSD accounted for reduced phosphoenolpyruvate carboxykinase, the rate-limiting step in gluconeogenesis [95]. On adipocytes, glucocorticoids potentiate adipogenesis and anabolic lipid metabolism and estrogens are described to have opposite effects [94]. Expression of 11beta-HSD1 in human adipocytes is induced by proinflammatory cytokines such as interleukin (IL) 1beta and tumor necrosis factor (TNF) alpha through signaling mechanisms including CCAAT/enhancer binding protein beta, MAPK/ERK kinase, and NFKappaB/RelA [96] and at least the latter two are also estrogen targets [46, 55], constituting a possible site of regulation.

4.4. Adipose Tissue Distribution. Estrogens regulate not only the amount of body fat accumulated but also its distribution among different depots. Men have lower amount of total body fat than women that, while in the premenopausal period, have a greater proportion of body fat accumulated in the subcutaneous (gluteofemoral) location than men, although in both genders the subcutaneous is the main site of accumulation [12, 79]. Thus men accumulate more fat in the visceral compartment compared to premenopausal women. However, after menopause, body fat is redistributed and women tend to acquire a body fat accumulation pattern similar to men [12, 50] and this redistribution may be linked to the age-related decrease in estrogen levels [93].

Premenopausal women are less prone to develop cardiovascular and metabolic diseases than age-matched men, illustrating estrogen protective effects [97, 98]. Men and postmenopausal women, whose estrogen levels are low, have increased metabolic risk translated into a higher likelihood to develop cardiovascular diseases, type 2 diabetes, and certain forms of cancer [99]. The increase in cardiometabolic risk after menopause is paralleled by the redistribution of body fat and is reversed or decreased by hormone replacement therapy (HRT) [50, 88, 100]. Frequently, several altered metabolic markers are clustered in the same individual justifying the increased risk. Probably one of the most prevalent alteration is visceral or central obesity, the main component of the metabolic syndrome, which also includes insulin resistance, low high density lipoprotein levels (HDL), hypertriglyceridemia, and hypertension [101].

AT pathogenicity markedly differs according to location of AT deposition (visceral or subcutaneous) [102]. Classical AT functions include heat insulation, mechanical cushioning, and storage of triacylglycerols [103]. Presently, it is known that the AT secretes endocrine, paracrine, and autocrine active substances in response to different stimuli [79, 104].
Some are specific to adipocytes, such as the adipokines leptin and adiponectin, and other may be produced by several cell types in the AT and include inflammatory cytokines (e.g., TNFalpha, IL6), chemokines (monocyte chemoattractant protein 1, MCP1), acute phase reactants, components of the alternative complement system, eicosanoids, and molecules with anti-inflammatory properties [105].

Visceral fat is a highly metabolic tissue. It is apparently more susceptible to lipolysis than subcutaneous AT [106] presenting denser irrigation and innervation than subcutaneous AT and draining secretions into the hepatic portal vein [107]. Excess accumulation of AT in the visceral compartment seems to independently predict insulin sensitivity [108–110], impaired glucose tolerance [111], elevated blood pressure [112, 113], and dyslipidemia [109, 114]. Regarding proinflammatory cytokines, visceral AT is associated with higher production of TNFalpha [106, 115], plasminogen activator inhibitor 1 (PAI1) [116], IL6, and CRP [117], while producing lower amounts of the anti-inflammatory, insulin-sensitizing adipokine adiponectin, which correlates more strongly with subcutaneous fat [118]. Currently, there is the suggestion that subcutaneous fat depots are protective [50, 88] and that the lack of AT, as evident in lipodystrophy [119], may equally lead to the development of metabolic syndrome.

Adipocytes from different depots differ in their capacity to produce estrogens, as aromatase expression declines from gluteofemoral, to subcutaneous abdominal, to visceral AT [120, 121]. Estrogens are secreted from AT in proportion to total fat mass [122] and are thought to signal the size of body energy stores and influence physiological processes through endocrine actions while also exerting important local effects through paracrine and autocrine actions.

The absence of estrogen production in the ovaries after menopause by increasing adiposity may augment AT synthesis of estrogens. It is known that obese postmenopausal women have higher serum estrogen concentration than lean postmenopausal women [123] and the proinflammatory condition associated with obesity may play a part in this association since aromatase is induced by cytokines such as TNFalpha [124]. Given 17beta-estradiol’s anti-inflammatory properties, for example, through suppression of IL6 or TNFalpha secretion by macrophages and dendritic cells [9], estrogens may have a paracrine role in AT inflammation targeted to alleviate potential tissue-damaging effects.

4.5. Changes in Estrogen Signaling and Availability. The absence of estrogens in animal and human models appears to favor the occurrence of the metabolic syndrome, starting with the facilitation of visceral AT deposition, which is reversed or prevented by estrogen reposition (Figure 3) [125].

Ovariectomy. Ovariectomy in laboratory animals results in the increase of AT accumulation, mainly visceral AT. Estrogen treatment in ovariectomized rats reduces adipocyte size by reducing fatty acid uptake, through a downregulation of lipoprotein lipase, and lipogenesis, downregulation of acetyl coenzyme A carboxylase, and fatty acids synthase [126]. Furthermore, the increase in fat mass is accompanied by a decrease in insulin sensitivity and glucose intolerance while circulating low density lipoprotein (LDL), triglycerides, fatty acids, and proinflammatory markers become elevated [127]. 17Beta-estradiol treatment reverses the impaired glucose tolerance, hyperglycemia, and reduced insulin release caused by ovariectomy in rats [128]. The protective effects of chronic 17beta-estradiol replacement on glucose intolerance are less obvious after feeding with normal diet than with high-fat diet in ovariectomized rats. However, 17beta-estradiol increased the transcription of IL6, TNFalpha, and plasminogen activator inhibitor 1 (PAI1) induced by high-fat diet in the liver and visceral AT, while maintaining the beneficial effect on glucose tolerance. These apparently contradictory results were interpreted as a dissociation between the metabolic and inflammatory effects of estrogens [129]. Table 1 summarizes the main effects of estrogens with relevance to metabolic inflammation.

Aromatase. Men with mutations leading to aromatase inactivation have central obesity and elevated plasma LDL cholesterol and triglycerides and insulin resistance revealed by high insulin in the presence of normal glucose levels [130]. Male...
Table 1: Comparison between the effects of ovariectomy and estrogen reposition for metabolic inflammation-related processes. 11beta-HSD1, 11beta-hydroxysteroid dehydrogenase.

| Ovariectomy                                              | Reversal by estrogen treatment                                                                 | References         |
|----------------------------------------------------------|------------------------------------------------------------------------------------------------|--------------------|
| Increases adipose tissue accumulation, mainly visceral, with increased adipocyte size | Yes Inhibition of key adipogenic genes, downregulation of lipoprotein lipase, and acetyl coenzyme A carboxylase and fatty acid synthase | [126, 187]         |
| Increases lipoprotein lipase and lipid deposition in adipocytes | Yes                                                                                          | [177]              |
| Increases food intake                                      | Yes                                                                                          | [12, 50]           |
| Reduces brain leptin sensitivity                           | Yes                                                                                          | [127]              |
| Results in Insulin resistance and glucose intolerance      | Yes                                                                                          | [127, 128, 187]    |
| Promotes hepatic steatosis                                | Yes                                                                                          | [187]              |
| Elevates low density lipoprotein, triglycerides, and fatty acids | Yes                                                                                          | [127]              |
| Elevates proinflammatory markers                          | Yes However, increased transcription of inflammatory mediators induced by high-fat diet in the liver and visceral AT-interpreted as a dissociation between the metabolic and inflammatory effects | [127, 129, 187]    |
| Increases hepatic 11beta-HSD1 activity and upregulates 11beta-HSD1 expression in visceral adipose tissue | Yes                                                                                          | [93, 214, 215]     |
| Increases visceral compared to subcutaneous 11beta-HSD1    | Increases subcutaneous compared to visceral 11beta-HSD1                                      |                    |

and female aromatase knockout mice also present metabolic dysfunction characterized by intraabdominal obesity, insulin resistance, dyslipidemia, and hepatic steatosis [78, 125, 131]. Hepatic steatosis was associated with impairment in fatty acid beta-oxidation, alterations that were reversed by administration of 17beta-estradiol [132].

**Estrogen Receptors.** ERalpha signaling mediates many important metabolic effects of estrogens both in males and in females. Several studies have shown associations between ERalpha polymorphisms and increased AT accumulation, particularly in the visceral compartment [133, 134]. In rodents, the inactivation of ERalpha is, in many aspects, similar to the loss of the aromatase gene. ERalpha or double ERalpha and -beta knockouts also show increased intraabdominal AT, adipocyte hypertrophy, insulin resistance, and decreased glucose tolerance independently of gender [135]. In addition, ERalpha knockouts have reduced oxygen uptake and caloric expenditure and present increased fasting insulin, leptin, and PAI1 levels while adiponectin is reduced under normal diet. Along with impaired glucose tolerance and skeletal muscle insulin resistance that are enhanced under high fat feeding, accumulation of bioactive lipid intermediates, inflammation, and diminished PPARalpha, PPARdelta, and uncoupling protein (UCP) 2 transcript levels are also evident [136]. Interestingly, ovariectomized ERalpha knockouts present a normalized homeostasis of circulating glucose and insulin levels and a reversal of the obese phenotype, proposing that ERbeta-associated estrogen action contributes to metabolic dysfunction. Indeed, ERbeta inactivation in mice leads to improved insulin sensitivity and glucose tolerance without increasing body fat content which supports the occurrence of opposite metabolic effects of estrogens on each of these receptors [137]. However, both ERalpha and ERbeta interfere with AT distribution, inflammation, fibrosis, and glucose homeostasis. Selective deletion of AT ERalpha in adult mice reproduces the findings from total body inactivation in ERalpha. More recently, a mouse model with ERalpha inactivation specifically in adipocytes (adipoERalpha) was generated. These mice displayed increased AT fibrosis and inflammation which was more marked in males, showing that the protective effects of estrogens on AT are dependent upon adipocyte ERalpha-mediated signaling [138].

**G Protein-Coupled Estrogen Receptor.** A role for GPER-mediated estrogen signaling in controlling energy homeostasis and development of obesity has been established [139]. GPER-deficient mice are also obese, supporting a role for GPER-dependent estrogen signaling in counteracting obesity development in both genders [140]. By 6 months of age GPER knockouts of both genders were obese, without changes in food intake or locomotor activity, and insulin resistant but only females exhibited glucose intolerance. At one year of age males had higher cholesterol, triglyceride levels and by two years of age had increased IL1beta, IL6, IL12, TNFalpha, MCP1, interferon gamma-induced protein 10, and monokine...
induced by interferon gamma and decreased adiponectin circulatory levels than wild type littermates [141]. GPER also modulates estrogen-related insulin release and beta-cell survival. GPER1 knockouts have impaired glucose tolerance and decreased glucose-stimulated insulin secretion [142] and 17beta-estradiol-stimulated insulin release is abolished in GPER1 knockout mice. Furthermore, part of the protective effects of estradiol on beta-cell death induced by oxidative stress are mediated through GPER estrogen signaling [143].

**Estrogen-Related Receptors.** ERRalpha regulates mitochondrial function and metabolism and has also been shown to mediate bone-derived macrophage activation by proinflammatory cytokines [144]. ERRalpha null mice are lean and resistant to high fat diet-induced obesity. In these mice, UCPI expression is upregulated in white AT possibly contributing to increased energy expenditure and lower body weight [57]. Acute-phase response induced by LPS, zymosan, or turpentine in mice reduced mRNA levels of ERRalpha, its coactivator, PPAR gamma coactivator 1 (PGC1) alpha, and medium-chain acyl-coenzyme A dehydrogenase, one of its targets, in the liver, heart, and kidney. This regulation was associated with the decrease in fatty acid oxidation and hypertriglyceridemia during inflammation and infection [145]. ERRgamma is another constitutively active transcription factor regulating genes involved in hepatic glucose metabolism and the endoplasmic reticulum stress. An interesting link between ERRgamma transcriptional activity and metabolic inflammation has been established by the demonstration that overexpression of this receptor led to regulation of cAMP responsive element-binding protein H (CREBH), an endoplasmic reticulum-bound transcription factor that mediates endoplasmic reticulum stress by increasing expression of acute-phase proteins in response to inflammation. Upon ERRgamma activation both CREBH and CRP expression were upregulated in a PGC1alpha-dependent manner, while ERRgamma knockdown or inhibition reduced these effects. Moreover, ERRgamma inhibition was also able to reduce augmented CRP gene expression in a model of obese diabetic animals [146].

**Estrogen Sulfotransferase and Steroid Sulfatase.** Estrogen sulfotransferase has been shown to have an important role in energy balance and type 2 diabetes pathogenesis [12]. Inactivation of estrogen sulfotransferase in female mice improves metabolic function in ob/ob, dexamethasone-, and high-fat diet-induced mouse models of type 2 diabetes. These mice display improvements of body composition, higher energy expenditure, and insulin sensitivity and decreased hepatic gluconeogenesis and lipogenesis compared to controls. These effects are abolished by ovariectomy and seem to result from increased estrogen availability and action on the liver. Metabolic improvement was only evident in females, whereas ob/ob males displayed worse metabolic profile than controls [147]. Estrogen sulfotransferase is present in abdominal subcutaneous AT of both obese males and females being positively correlated with mRNA levels T NFalpha and suppressor of cytokine signaling 3, suggesting its association with inflammation [148]. Corroborating this assumption, functional depletion of estrogen sulfotransferase in the human umbilical vein endothelial cell line resulted in regulation of genes involved in inflammation and lipid metabolism. Anti-inflammatory cytokines (IL4 and IL10) were upregulated and proinflammatory cytokines were downregulated (TNFalpha, IL1beta, and IL6, among others) and genes involved in cholesterol uptake and cholesterol ester synthesis were also increased. This regulation was attenuated by PPARgamma knockdown or antagonism, meaning that sulfotransferase activity upregulates PPARgamma in the presence of 17beta-estradiol [149]. Steroid sulfatase-mediated desulfation is another mechanism that modifies estrogen availability, regulating its actions. In genetic (ob/ob) or environmental (high-fat diet-induced) models of obesity or of type 2 diabetes steroid sulfatase was induced in the liver. This increase of steroid sulfatase in the liver of transgenic mice has been interpreted as a mechanism to counterbalance metabolic dysfunction, since overexpression alleviated dysmetabolism in high-fat diet and ob/ob models of obesity and type 2 diabetes, resulting in reduced body weight, improved insulin sensitivity, and decreased hepatic steatosis and inflammation. This protection in females was proposed to be mediated through reactivation of circulating estrogen sulfates to active estrogens what was supported by the observation that metabolic amelioration induced by steroid sulfatase overexpression was lost in ovariectomized rats [150].

**Hormone Replacement Therapy.** It is generally accepted that a great part of the increase in cardiometabolic risk after menopause is accounted for by the decline in ovarian production of estrogens and accumulating evidence argues in favor of risk reduction with HRT [151]. Despite the report from Women’s Health Initiative of increased incidence of cardiovascular events in postmenopausal women with ages between 50 and 79 receiving HRT [152] having led to the early termination of this large-scale trial, further analysis of study data, separating cohorts by age, revealed a protection in women with fewer menopausal years (50 to 59 years of age) [153]. Presently, extensive research supports that HRT has an important impact on both metabolic and inflammatory processes [151]. In postmenopausal women, estrogen therapy decreased the expression of genes involved in lipogenesis including acetyl-coenzyme A carboxylase, sterol regulatory element-binding protein 1c, stearoyl-CoA desaturase, lipoprotein lipase, fatty acid synthase, fatty acid desaturase, and PPARgamma in human abdominal AT [154, 155]. Conjugated estrogens and estradiol administered to postmenopausal women led to an increase in glucose disposal during hyperinsulinemic-euglycemic clamp studies [156, 157]. Human studies have also reported increased circulatory cytokine levels after menopause, including TNFalpha, IL1, and IL6, these levels being substantially lower in women receiving HRT [158]. In parallel, plasma levels of MCP1 have been reported to be lower in postmenopausal women receiving HRT compared to those not receiving HRT [159]. The observation that HRT results in increased CRP led to the suggestion that it induces inflammation that may be responsible for acute cardiovascular events. However, by evaluating
vascular inflammation markers in postmenopausal women with increased cardiovascular risk after HRT or no HRT, it was demonstrated that although CRP levels did increase after HRT, all other inflammation markers were decreased (soluble intracellular adhesion molecule 1, vascular cell adhesion molecule 1, E-selectin, and IL6), while no significant changes were observed in women not taking HRT. The authors concluded that metabolic hepatic activation is responsible for increased CRP instead of an acute-phase response and that HRT overall decreases vascular inflammation [160]. Another important addition to this debate is the fact that a formulation that includes a progestin could exert a dose-dependent inhibitory effect on circulating adiponectin and that women with central obesity, which is also associated with the highest levels of free estrogens, or with insulin resistance may not benefit from estrogen progestin therapy [161]. Furthermore, the effect of HRT upon plasma inflammation markers may be dependent upon route of administration, since oral therapy has been shown to be associated with better inflammatory profile than transdermal therapy [162].

4.6. Estrogens and Adipose Tissue Cellularity. Obesity is described to be the result of an increase in the number and in the size of adipocytes [163]. Indeed, these are defining features of obesity as this dynamic organ expands to store excess energy. Consequently, for some time it was believed that decreasing both adipose hyperplasia and hypertrophy were necessary measures to overcome obesity and its complications. However that concept is no longer defensible since it was demonstrated that AT expandability is needed to buffer nutrient excess and only when this capacity becomes exceeded other disturbances arise [28, 164–167]. In this regard, an “unorthodox therapeutic strategy” for the treatment of obesity-associated metabolic complications has been proposed: to increase adipocyte recruitment and facilitate the development of hyperplastic forms of AT [168].

Indeed, hypertrophic AT growth seems to associate with adipocyte dysfunction resulting in obesity-related metabolic disorders. In hypertrophic cells, both mechanic and hypoxic stresses are increased inducing the production and release of proinflammatory molecules and predisposing cells to apoptotic death or necrotic cell rupture [28, 164, 169]. This has been considered one of the most plausible causes of inflammatory cell recruitment to AT of obese animals where macrophages surround dead adipocytes [170]. For each dead adipocyte, several macrophages are recruited [171], implying a large amplification of the inflammatory response since macrophages are thought to locally produce inflammatory mediators. Moreover, it has been proposed that visceral AT growth is mainly due to hypertrophy, while in other locations there may be mainly growth through hyperplasia [172]. Illustrating hypertrophic AT pathogenicity, bigger adipocytes are found in insulin resistant patients [173] and adipocyte size is positively correlated with plasma levels of TNFalpha, IL6, and high sensitivity CRP levels and negatively correlated with adiponectin [174]. Furthermore, the insulin-sensitizing anti-inflammatory thiazolidinediones have a proadipogenic effect, resulting in a higher capacity of fat storage by the AT [168]. Curiously, it has been shown that macrophage infiltration on the AT is markedly reduced after surgery-induced weight loss in morbidly obese individuals, the remaining macrophages expressing anti-inflammatory cytokines like IL10 [175].

The determination of adipocyte size depends on the balance between the lipogenic and lipolytic pathways but also on the rate of adipocyte proliferation and differentiation and estrogens influence all these processes [76]. The stromal fraction of AT is composed of several cell types, including preadipocytes and endothelial and vascular smooth muscle cells, most of which respond to estrogens in the surrounding environment, some being able to produce them [76, 176]. Estrogens can directly inhibit AT deposition by decreasing lipogenesis. This effect results mainly from decreasing activity of lipoprotein lipase. Ovariectomy increases lipoprotein lipase and lipid deposition in adipocytes and 17beta-estradiol reverses this increase [177]. On the other hand, 17beta-estradiol can indirectly affect lipolysis by inducing the lipolytic enzyme hormone-sensitive lipase [178] or by increasing the lipolytic effects of adrenaline [179]. Moreover fatty acid oxidation might also be increased, which might contribute to the decrease in AT mass induced by 17beta-estradiol. However, contrary to its anti- and lipolytic effect, estrogen attenuates the lipolytic effects of adrenaline on the subcutaneous AT by increasing the expression of alpha2aA-adrenergic receptors the subcutaneous AT [79]. This effect could in part account for the increase deposition of subcutaneous AT in women compared to men [180]. Estrogen effects in the inhibition of lipogenesis and triglyceride accumulation are also evident after high-fat diet feeding [181].

In the AT, the highest aromatase expression is found in preadipocytes although vascular cells also present aromatase activity [176]. As preadipocytes undergo differentiation, aromatase expression decreases being almost undetectable in fully differentiated adipocytes [30]. Thus the higher estrogen production by the subcutaneous AT may constitute a marker of functional AT that retains its capacity to buffer nutrient excess and avoid visceral obesity and ectopic fat accumulation.

Estrogen signaling through inositol-3-phosphate pathway is involved in preadipocyte proliferation and differentiation into mature adipocytes [182]. These effects are likely to involve ERalpha, protein kinase C, and MAPK. Despite this description, estrogen effects on proliferation are still not very clear. These hormones have been shown to decrease preadipocyte number, particularly by limiting the exaggerated rate of cell divisions that occurs in their absence [76]. On the other hand, during puberty, women acquire more AT, characterized by hyperplasia [183]. Increased overall AT mass in women partially reflects a greater number of adipocytes compared to men pointing towards a role of estrogens in adipocyte development and establishment of adult adipocyte number, as well as in the modulation of adipocyte size in adult females. Similarly 17beta-estradiol stimulates proliferation of subcutaneous rat preadipocytes from females, but not males, and the same phenomenon occurs in human-derived cells [184]. Accordingly, 17beta-estradiol may act as an important local factor influencing the proliferation of preadipocytes that may affect adipocyte number in a depot- and gender-specific manner in human abdominal subcutaneous and omental AT.
Moreover, both male and female ERalpha knockouts have large increases in fat pad weight, which results from hyperplasia more than hypertrophy of adipocytes [186]. Similar results were seen in aromatase knockout mice [78], in which the lack of estrogen signaling led to a large increase in the number of adipocytes, demonstrating that estrogen normally plays an inhibitory role during adipogenesis to limit adipocyte number.

Concerning differentiation, results also point to different directions. There is evidence that estrogens are proadipogenic hormones while some studies show that estrogens inhibit estrogen differentiation [76]. However, despite being considered to facilitate preadipocyte differentiation, they are usually related to a decrease in total body fat and in adipocyte hypertrophy [76]. In nonovariectomized female and ovariectomized female mice supplemented with estrogen there is a strong inhibition of key adipogenic genes. However, male mice and ovariectomized females gain weight predominately in the form of abdominal AT possibly due to an increase in adipocyte size [187]. Notwithstanding, it is possible that the reported decrease in adipogenic genes reflects the hyperplastic, rather than hypertrophic nature of AT under the influence of estrogens, a shift that may underlie many of the metabolic and inflammatory benefits of these hormones.

4.7 Estrogens and Inflammatory Cells. The increase in the number of AT macrophages in obesity has been set into attention with the work of Weisberg et al. [188]. Several differences have been encountered between sites of AT deposition both in the type and number of inflammatory cells that they may host and in the production and integration of metabolic and inflammatory signals. Both in humans and in rodents, adipocyte size is a strong and direct predictor of macrophage accumulation in the AT [189, 190]. When the diameter of adipocytes increases and the ability of adipocytes to expand reaches a limit AND fail accommodate the excess of nutrients, cells become a source of adipokines such as TNFalpha, IL6, and MCP1, consolidating the perpetuation of inflammation. Macrophage infiltration was found to be higher in visceral compared with subcutaneous fat pads in a mouse model of obesity and correlated with adipocyte size [188, 191]. However, omental adipocytes exhibit smaller adipose cell size than subcutaneous ones, showing that adipocyte hypertrophy is not the sole determinant of macrophage recruitment to the AT, highlighting the importance of factors related AT location [189, 190]. It has also been shown that most of the inflammatory cytokine production from the AT of obese individuals is derived from inflammatory rather than from adipose cells [1]. This suggests that these cells have paramount importance in the genesis of obesity complications and infiltration of the AT by macrophages constitutes also an important point of possible regulation by estrogens.

ERalpha and ERbeta are present in monocytes and macrophages, and estrogens activate these cells [70, 192]. Apparently, peripheral blood mononuclear cells (PBMCs) with exception of monocytes of postmenopausal women have similar ER expression patterns compared to those of premenopausal females. ERalpha is higher in monocytes from postmenopausal women which may result in altered estrogen responsiveness compared with monocytes from premenopausal women [193]. However, results on the effect of estrogens on PBMCs are also conflicting. After menopause, IL6 expression may be present in nonstimulated PBMC isolated directly from venous blood, which suggests the possibility of an endogenous activation of these cells in vivo, possibly due to the absence of circulating estrogens [194]. In the presence of LPS, 17beta-estradiol inhibited TNFalpha secretion from PBMCs at concentrations of $10^{-10}$ to $10^{-7}$ mol $L^{-1}$ in male subjects and at $10^{-8}$ to $10^{-7}$ mol $L^{-1}$ in female subjects but had a stimulating effect in the absence of LPS [195]. In human whole blood cultures, 17beta-estradiol at $10^{-10}$ to $10^{-8}$ mol $L^{-1}$ decreased spontaneous secretion of IL6, TNFalpha, IL1 receptor antagonist, IL1beta, and the ratio of IL1beta/IL1 receptor antagonist compared with control, but 17beta-estradiol did not strongly change LPS-stimulated cytokine secretion [196].

Most ER-dependent immune effects attributed to 17beta-estradiol in macrophages are thought to be mediated through ERalpha and not ERbeta [9, 197–199]. This has been widely supported by the findings of Ribas et al. [200]. Particularly, hematopoietic or myeloid-specific ERalpha deletion in mice displayed altered plasma adipokine and cytokine levels, glucose intolerance, insulin resistance, and increased AT mass. Moreover, LDL receptor-knockout mice transplanted with ERalpha null bone marrow presented a similar obese phenotype. Also, ERalpha was shown to mediate estrogens effects on inflammation attenuation, IL4-mediated induction of alternative activation, and maintenance of macrophage function [200]. In addition, GPER is also highly expressed in human macrophages [201].

Tissue macrophages can be classically (M1) or alternatively (M2) activated, expressing a profile of pro- and anti-inflammatory cytokines, respectively. Stimulation of macrophages with $T_{H1}$ cytokines such as interferon gamma or LPS promotes classical activation of macrophages, which have a high inflammatory and bactericidal potential, characterized by the release of TNFalpha, IL6, and reactive oxygen species. However, $T_{H2}$ cytokines, including IL4 and IL13, promote the alternative activation of macrophages, which have high antiparasitic capability and produce factors such as IL10, IL1 receptor antagonist, arginase, and transforming growth factor beta. M2 macrophages are also involved in remodeling (repair) of AT and lipid metabolism [189, 191]. Newly recruited AT macrophages display a more proinflammatory profile than resident AT macrophages in lean mice [202] and resident macrophages express genes characteristic of the M2 activation state [203, 204].

Macrophage differentiation strongly depends upon the local microenvironment. In activated macrophages, estrogens effects are primarily repressive, by inhibiting the expression of genes for cytokines or modulating other inflammatory mediators by the ER-dependent and/or nongenomic pathways in response to inflammatory signals [197, 205, 206]. Further, the majority of studies have only addressed the effect of estrogens on classically activated M1 cells and less is known about the effect on alternatively activated macrophages. The roles of estrogens in the macrophage-related inflammation are clearly complex. In mice, estrogens inhibit LPS-induced
Figure 4: Estrogens effects on metabolic improvement may be cause (a) or consequence (b) of regulation of inflammation pathways. Further studies are needed to ascertain the relationship between estrogen signaling, inflammation, and metabolism. It is possible that the anti-inflammatory effects of estrogens, though their influences on processes like energy balance, leptin and glucocorticoid signaling, adipose tissue distribution and cellularity, and activity of immune cells, may culminate on metabolic improvement. However, estrogens have also been demonstrated to directly interfere with such processes, favoring improved inflammatory profile that results in overall metabolic amelioration. Additionally, the two hypotheses are not mutually exclusive. AT: adipose tissue.

Figure 5: Effects of xenoestrogens on inflammation may mediate their actions on metabolism.

5. Concluding Remarks

Evidence on the ability of estrogens to modulate metabolism-related inflammation is accumulating, although many questions remain unanswered. The independent influence of these hormones on each of these isolated areas of research is much more solid than the understanding that, through the modulation of inflammatory processes, estrogens are able to influence metabolic dysfunction. However, the relationship between estrogens and metabolism are reciprocal since the metabolic control favored by estrogens avoids the establishment of metabolic inflammation (Figure 4). The interdependence of both processes makes the studies of these matters elaborate as do the variation of estrogens’ effects with timing of treatment, dose, type of estrogen used, physiological state of the organism, body composition, gender and availability of other hormones, and the multiple cellular pathways available for estrogen signaling. The recent demonstration of ubiquitous presence in living organism of xenobiotic molecules with endocrine disrupting properties with the ability to change estrogen signaling and largely impact on metabolism also deserves attention and may provide clues to the epidemic growth of obesity-related metabolic complications (Figure 5) [210–213]. Even so, there is general agreement that estrogens improve inflammation related to metabolic dysfunction and, although it seems evident that it acts indirectly through metabolic amelioration, the direct regulation of inflammation pathways is also documented. However, much work still needs to be performed in this respect to allow broadening the knowledge on estrogens’ mechanisms of action and establishing the rationale for the development and use of estrogen signaling modulation as a therapeutic tool for metabolic improvement. Looking at the advances made on sister areas of research such as those related to the study of the inflammation-modulatory effects of estrogens on cardiovascular and neurodegenerative diseases and cancer [70, 72, 74] will possibly bring new additions to the mechanisms of estrogens’ actions in metabolism.

Abbreviations

AT: Adipose tissue
CREB: cAMP-related element binding
CREBH: cAMP responsive element-binding protein H
CPR: C-reactive protein  
ER: Estrogen receptor  
ERE: Estrogen response element  
ERR: Estrogen-related receptor  
GPER: G protein-coupled estrogen receptor  
HRT: Hormone replacement therapy  
IkappaB: Inhibitor of kappaB  
IKK: Inhibitor of kappaB kinase  
IL: Interleukin  
JNK: c-jun N-terminal kinase  
LDL: Low density lipoprotein  
MAPK: Mitogen-activated protein kinase  
M1: Classically activated macrophages  
M2: Alternatively activated macrophages  
MCPI: Monocyte chemoattractant protein 1  
NAFLD: Nonalcoholic fatty liver disease  
NFkappaB: Nuclear factor kappaB  
NO: Nitric oxide  
PAI1: Plasminogen activator inhibitor 1  
PGC1: Peroxisome proliferator-activated receptor  
PI3K: Phosphoinositide 3-kinase  
PPAR: Peroxisome proliferator-activated receptor  
PI3K: Phosphoinositide 3-kinase  
PPAR: Peroxisome proliferator-activated receptor  
TF: Transcription factor  
TLR: Toll-like receptor  
TNF: Tumor necrosis factor  
UCP: Uncoupling protein  
17Beta-HSD: 17Beta-hydroxysteroid dehydrogenase.

Conflict of Interests

The authors declare that there is no conflict of interests that could be perceived as prejudicing the impartiality of the research reported.

Acknowledgment

This work was supported by Fundação para a Ciência e a Tecnologia (Fundo Social Europeu, Programa Operacional Potencial Humano da UE (POPH); PEst-OE/SAU/UI0038/2014; SFRH/BPD/40110/2007; SFRH/BD/64691/2009).

References

[1] G. S. Hotamisligil, “Inflammation and metabolic disorders,” *Nature*, vol. 444, no. 7121, pp. 860–867, 2006.

[2] D. Mathis and S. E. Shoelson, “Immunometabolism: an emerging frontier,” *Nature Reviews Immunology*, vol. 11, no. 2, pp. 81–83, 2011.

[3] M. F. Gregor and G. S. Hotamisligil, “Inflammatory mechanisms in obesity,” Annual Review of Immunology, vol. 29, pp. 415–445, 2011.

[4] A. Schäffler, J. Schölmerich, and B. Salzberger, “Adipose tissue as an immunological organ: toll-like receptors, C1q/TNFs and CTRPs,” *Trends in Immunology*, vol. 28, no. 9, pp. 393–399, 2007.

[5] R. Monteiro, “Chronic inflammation in the metabolic syndrome—emphasis on adipose tissue,” in *Oxidative Stress, Inflammation and Angiogenesis in the Metabolic Syndrome*, R. Soares and C. Costa, Eds., pp. 65–83, Springer, London, UK, 2009.

[6] R. Monteiro and I. Azevedo, “Chronic inflammation in obesity and the metabolic syndrome,” *Mediators of Inflammation*, vol. 2010, Article ID 289645, 10 pages, 2010.

[7] O. Osborn and J. M. Olefsky, “The cellular and signaling networks linking the immune system and metabolism in disease,” *Nature Medicine*, vol. 18, no. 3, pp. 363–374, 2012.

[8] K. E. Wullen and G. S. Hotamisligil, “Inflammation, stress, and diabetes,” *The Journal of Clinical Investigation*, vol. 115, no. 5, pp. 1111–1119, 2005.

[9] R. H. Straub, “The complex role of estrogens in inflammation,” *Endocrine Reviews*, vol. 28, no. 5, pp. 521–574, 2007.

[10] E. M. Sternberg, “Neuroendocrine regulation of autoimmune/inflammatory disease,” *Journal of Endocrinology*, vol. 169, no. 3, pp. 429–435, 2001.

[11] E. Simpson, M. Jones, M. Misso et al., “Estrogen, a fundamental player in energy homeostasis,” *The Journal of Steroid Biochemistry and Molecular Biology*, vol. 95, no. 1–5, pp. 3–8, 2005.

[12] F. Mauvais-Jarvis, D. J. Clegg, and A. L. Hevener, “The role of estrogens in control of energy balance and glucose homeostasis,” *Endocrine Reviews*, vol. 34, no. 3, pp. 309–338, 2013.

[13] M. Qatanani and M. A. Lazar, “Mechanisms of obesity-associated insulin resistance: many choices on the menu,” *Genes & Development*, vol. 21, no. 12, pp. 1443–1455, 2007.

[14] A. Rudich, H. Kanety, and N. Bashan, “Adipose stress-sensing kinases: linking obesity to malfunction,” *Trends in Endocrinology and Metabolism*, vol. 18, no. 8, pp. 291–299, 2007.

[15] R. Medzhitov, “Origin and physiological roles of inflammation,” *Nature*, vol. 454, no. 7203, pp. 428–435, 2008.

[16] R. P. Tracy, “Inflammation, the metabolic syndrome and cardiovascular risk,” *International Journal of Clinical Practice, Supplement*, no. 134, pp. 10–17, 2003.

[17] A. Guillemé, J. V. Virbasius, V. Puri, and M. P. Czech, “Adipocyte dysfunctions linking obesity to insulin resistance and type 2 diabetes,” *Nature Reviews Molecular Cell Biology*, vol. 9, no. 5, pp. 367–377, 2008.

[18] K. Zhang and R. J. Kaufman, “From endoplasmic-reticulum stress to the inflammatory response,” *Nature*, vol. 454, no. 7203, pp. 455–462, 2008.

[19] C. N. Lumeng and A. R. Saltiel, “Inflammatory links between obesity and metabolic disease,” *Journal of Clinical Investigation*, vol. 121, no. 6, pp. 2111–2117, 2011.

[20] J. Chmelar, K.-J. Chung, and T. Chavakis, “The role of innate immune cells in obese adipose tissue inflammation and development of insulin resistance,” *Thrombosis & Haemostasis*, vol. 109, no. 3, pp. 399–406, 2013.

[21] E. Fuentes, F. Fuentes, G. Vilahur, L. Badimon, and I. Palomo, “Mechanisms of chronic state of inflammation as mediators that link obese adipose tissue and metabolic syndrome,” *Mediators of Inflammation*, vol. 2013, Article ID 136584, 11 pages, 2013.

[22] J. N. Fain, A. K. Madan, M. L. Hiler, P. Cheema, and S. W. Bahouth, “Comparison of the release of adipokines by adipose tissue, adipose tissue matrix, and adipocytes from visceral and subcutaneous abdominal adipose tissues of obese humans,” *Endocrinology*, vol. 145, no. 5, pp. 2273–2282, 2004.

[23] P. D. Cani, J. Amar, M. A. Iglesias et al., “Metabolic endotoxemia initiates obesity and insulin resistance,” *Diabetes*, vol. 56, no. 7, pp. 1761–1772, 2007.

[24] C. Erridge, T. Attina, C. M. Spickett, and D. J. Webb, “A high-fat meal induces low-grade endotoxia: evidence of a
novel mechanism of postprandial inflammation," *The American Journal of Clinical Nutrition*, vol. 86, no. 5, pp. 1286–1292, 2007.

[25] G. Boden and G. I. Shulman, "Free fatty acids in obesity and type 2 diabetes: defining their role in the development of insulin resistance and β-cell dysfunction," *European Journal of Clinical Investigation*, vol. 32, no. 3, pp. 14–23, 2002.

[26] A. Iyer, D. P. Fairlie, J. B. Prins, B. D. Hammock, and L. Brown, "Inflammatory lipid mediators in adipocyte function and obesity," *Nature Reviews Endocrinology*, vol. 6, no. 2, pp. 71–82, 2010.

[27] J. Ye, "Emerging role of adipose tissue hypoxia in obesity and insulin resistance," *International Journal of Obesity*, vol. 33, no. 1, pp. 54–66, 2009.

[28] R. Monteiro, R. Soares, S. Guerreiro, D. Pestana, C. Calhau, and I. Azevedo, "Adipocyte size and liability to cell death," *Obesity Surgery*, vol. 16, no. 6, pp. 804–806, 2006.

[29] R. Monteiro, R. Soares, S. Guerreiro, D. Pestana, C. Calhau, and I. Azevedo, "Red wine increases adipose tissue aromatase expression and regulates body weight and adipocyte size," *Nutrition*, vol. 25, no. 6, pp. 699–705, 2009.

[30] E. R. Simpson, C. Clyne, G. Rubin et al., "Aromatase—a brief overview," *Annual Review of Physiology*, vol. 64, pp. 93–127, 2002.

[31] K. C. Reed and S. Ohno, "Kinetic properties of human placental aromatase. Application of an assay measuring 3H₂O release from 1β,2β, 3H androgens," *Journal of Biological Chemistry*, vol. 251, no. 6, pp. 1625–1631, 1976.

[32] S. Chen, "Aromatase and breast cancer," *Frontiers in Bioscience*, vol. 3, pp. d922–d933, 1998.

[33] H. Matsumine, K. Hirato, T. Yanaihara, T. Tamada, and M. Yoshida, "Aromatization by skeletal muscle," *The Journal of Clinical Endocrinology and Metabolism*, vol. 63, no. 3, pp. 717–720, 1986.

[34] E. Labrie, A. Bélanger, V. Luu-The et al., "DHEA and the intracrine formation of androgens and estrogens in peripheral target tissues: its role during aging," *Steroids*, vol. 63, no. 5–6, pp. 322–328, 1998.

[35] A. M. Corbould, M. J. Bawden, T. C. Lavranos, R. J. Rodgers, and S. J. Judd, "The effect of obesity on the ratio of type 3 17β-hydroxysteroid dehydrogenase mRNA to cytochrome P450 aromatase mRNA in subcutaneous abdominal and intra-abdominal adipose tissue of women," *International Journal of Obesity*, vol. 26, no. 2, pp. 165–175, 2002.

[36] T. Saloniemi, H. Jokela, L. Strauss, P. Pakarinen, and M. Poussinen, "The diversity of sex steroid action: novel functions of hydroxysteroid (17β) dehydrogenases as revealed by genetically modified mouse models," *Journal of Endocrinology*, vol. 212, no. 1, pp. 27–40, 2012.

[37] H. G. Burger, "The endocrinology of the menopause," *The Journal of Steroid Biochemistry and Molecular Biology*, vol. 69, no. 1–6, pp. 31–35, 1999.

[38] E. R. Simpson, Y. Zhao, V. R. Agarwal et al., "Aromatase expression in health and disease," *Recent Progress in Hormone Research*, vol. 52, pp. 185–213, 1997.

[39] A. Meseguer, C. Puche, and A. Cabero, "Sex steroid biosynthesis in white adipose tissue," *Hormone and Metabolic Research*, vol. 34, no. 11-12, pp. 731–736, 2002.

[40] C. Bélanger, V. Luu-The, P. Dupont, and A. Tchernof, "Adipose tissue intracrinology: potential importance of local androgen/estrogen metabolism in the regulation of adiposity," *Hormone and Metabolic Research*, vol. 34, no. 11-12, pp. 737–745, 2002.

[41] E. R. Simpson, "Sources of estrogen and their importance," *Journal of Steroid Biochemistry and Molecular Biology*, vol. 86, no. 3–5, pp. 225–230, 2003.

[42] M. J. Reed, A. Purohit, L. W. L. Woo, S. P. Newman, and B. V. L. Potter, "Steroid sulfatase: molecular biology, regulation, and inhibition," *Endocrine Reviews*, vol. 26, no. 2, pp. 171–202, 2005.

[43] M. H. Faulds, C. Zhao, K. Dahlman-Wright, and J.-Å. Gustafsson, "The diversity of sex steroid action: regulation of metabolism by estrogen signaling," *Journal of Endocrinology*, vol. 212, no. 1, pp. 3–12, 2012.

[44] S. Green, V. Kumar, A. Krust, P. Walter, and P. Chambon, "Structural and functional domains of the estrogen receptor," *Cold Spring Harbor Symposia on Quantitative Biology*, vol. 51, no. 2, pp. 751–758, 1986.

[45] G. G. Kuiper, E. Enmark, M. Pelto-Huikko, S. Nilsson, and J.-Å. Gustafsson, "Cloning of a novel receptor expressed in rat prostate and ovary," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 93, no. 12, pp. 5925–5930, 1996.

[46] J. P. Stice and A. A. Knowlton, "Estrogen, NfκB, and the heat shock response," *Molecular Medicine*, vol. 14, no. 7–8, pp. 517–527, 2008.

[47] G. G. J. Muiker, B. Carlsson, K. Grandien et al., "Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors α and β," *Endocrinology*, vol. 138, no. 3, pp. 863–870, 1997.

[48] A. Foryst-Ludwig and U. Kintscher, "Metabolic impact of estrogen signalling through ERalpha and ERbeta," *The Journal of Steroid Biochemistry and Molecular Biology*, vol. 122, no. 1–3, pp. 74–81, 2010.

[49] J. Frasor, D. H. Barnett, J. M. Danes, R. Hess, A. F. Parlow, and B. S. Katzenellenbogen, "Response-specific and ligand dose-dependent modulation of estrogen receptor (ER) activity by ERβ in the uterus," *Endocrinology*, vol. 144, no. 7, pp. 3159–3166, 2003.

[50] E. Mauvais-Jarvis, "Estrogen and androgen receptors: regulators of fuel homeostasis and emerging targets for diabetes and obesity," *Trends in Endocrinology and Metabolism*, vol. 22, no. 1, pp. 24–33, 2011.

[51] E. J. Filardo, J. A. Quinn, K. I. Bland, and A. R. Frackelton Jr., "Estrogen-induced activation of Erk-1 and Erk-2 requires the G protein-coupled receptor homolog, GPR30, and occurs via trans-activation of the epidermal growth factor receptor through release of HB-EGF," *Molecular Endocrinology*, vol. 14, no. 10, pp. 1649–1660, 2000.

[52] S. M. Aronica, W. L. Kraus, and B. S. Katzenellenbogen, "Estrogen action via the cAMP signaling pathway: stimulation of adenylate cyclase and cAMP-regulated gene transcription," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 91, no. 18, pp. 8517–8521, 1994.

[53] C. M. Doolan and B. J. Harvey, "A Gs protein-coupled membrane receptor, distinct from the classical oestrogen receptor, transduces rapid effects of oestradiol on [Ca²⁺]₅, in female rat distal colon," *Molecular and Cellular Endocrinology*, vol. 199, no. 1-2, pp. 87–103, 2003.

[54] W. A. Carlezon Jr., R. S. Duman, and E. J. Nestler, "The many faces of CREB," *Trends in Neurosciences*, vol. 28, no. 8, pp. 436–445, 2005.

[55] E. Filardo, J. Quinn, Y. Pang et al., "Activation of the novel estrogen receptor G protein-coupled receptor 30 (GPR30) at the plasma membrane," *Endocrinology*, vol. 148, no. 7, pp. 3236–3245, 2007.
Mediators of Inflammation

[56] C. M. Revankar, D. F. Cimino, L. A. Sklar, J. B. Arterburn, and E. R. Prossnitz, “A transmembrane intracellular estrogen receptor mediates rapid cell signaling,” Science, vol. 307, no. 5715, pp. 1625–1630, 2005.

[57] V. Giguère, “Transcriptional control of energy homeostasis by the estrogen-related receptors,” Endocrine Reviews, vol. 29, no. 6, pp. 677–696, 2008.

[58] J. A. Villena and A. Krali, “ERRα: a metabolic function for the oldest orphan,” Trends in Endocrinology & Metabolism, vol. 19, no. 8, pp. 269–276, 2008.

[59] R. J. Steffan, E. Matelan, M. A. Ashwell et al., “Control of chronic inflammation with pathway selective estrogen receptor ligands,” Current Topics in Medicinal Chemistry, vol. 6, no. 2, pp. 103–111, 2006.

[60] J. P. Stice, F. N. Mbai, L. Chen, and A. A. Knowlton, “Rapid activation of nuclear factor κB by 17β-estradiol and selective estrogen receptor modulators: pathways mediating cellular protection,” Shock, vol. 38, no. 2, pp. 128–136, 2012.

[61] R. Galien and T. Garcia, “Estrogen receptor impairs interleukin-6 expression by preventing protein binding on the NF-κB site,” Nucleic Acids Research, vol. 25, no. 12, pp. 2424–2429, 1997.

[62] B. Stein and M. X. Yang, “Repression of the interleukin-6 promoter by estrogen receptor is mediated by NF-κB and C/EBPβ,” Molecular & Cellular Biology, vol. 15, no. 9, pp. 4971–4979, 1995.

[63] O. Guzeloglu-Kayisli, G. Halis, S. Taskiran, U. A. Kayisli, and A. Arici, “DNA-binding ability of NF-κB and its activation results in inhibition of estrogen responsiveness,” Reproductive Sciences, vol. 15, no. 5, pp. 493–505, 2008.

[64] M. J. Evans, A. Eckert, K. Lai, S. J. Adelman, and D. C. Harnish, “Reciprocal antagonism between estrogen receptor and NF-κB activity in vivo,” Circulation Research, vol. 89, no. 9, pp. 823–830, 2001.

[65] D. Xing, S. Oparil, H. Y. Yu et al., “Estrogen modulates NFκB signaling by enhancing IkκB levels and blocking p65 binding at the promoters of inflammatory genes via estrogen receptor-β,” PLoS ONE, vol. 7, no. 6, Article ID e36890, 2012.

[66] R. C. Dodel, Y. Du, K. R. Bales, F. Gao, and S. M. Paul, “Sodium salicylate and 17β-estradiol attenuate transcription factor NF-κB translocation in cultured rat astroglial cultures following exposure to amyloid Aβ1-40 and lipopolysaccharides,” Journal of Neurochemistry, vol. 73, no. 4, pp. 1453–1460, 1999.

[67] T. Simoncini, S. Maffei, G. Basta et al., “Estrogens and glucocorticoids inhibit endothelial vascular cell adhesion molecule-1 expression by different transcriptional mechanisms,” Circulation Research, vol. 87, no. 1, pp. 19–25, 2000.

[68] Y. Wen, S. Yang, R. Liu et al., “Estrogen attenuates nuclear factor-kappa B activation induced by transient cerebral ischemia,” Brain Research, vol. 1008, no. 2, pp. 147–154, 2004.

[69] C.-J. Liu, J.-F. Lo, C.-H. Kuo et al., “Akt mediates 17β-estradiol and/or estrogen receptor-α inhibition of LPS-induced tumor necrosis factor-α expression and myocardial cell apoptosis by suppressing the JNK1/2-NFκB pathway,” Journal of Cellular and Molecular Medicine, vol. 13, no. 9, pp. 3655–3667, 2009.

[70] S. Poźni, V. Benedusi, A. Maggi, and E. Vegeto, “Estrogen action in neuroprotection and brain inflammation,” Annals of the New York Academy of Sciences, vol. 1089, pp. 302–323, 2006.

[71] R. M. Ritzel, L. A. Capozzi, and L. D. McCullough, “Sex, stroke, and inflammation: the potential for estrogen-mediated immunoprotection in stroke,” Hormones and Behavior, vol. 63, no. 2, pp. 238–253, 2013.

[72] M. L. Slattery and F. A. Fitzpatrick, “Convergence of hormones, inflammation, and energy-related factors: a novel pathway of cancer etiology,” Cancer Prevention Research, vol. 2, no. 11, pp. 922–930, 2009.

[73] M. N. Weitzmann and R. Pacifici, “Estrogen deficiency and bone loss: an inflammatory tale,” Journal of Clinical Investigation, vol. 116, no. 5, pp. 1186–1194, 2006.

[74] D. Xing, S. Nozell, Y.-F. Chen, F. Hage, and S. Oparil, “Estrogen and mechanisms of vascular protection,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 29, no. 3, pp. 289–295, 2009.

[75] N. Ouchi, J. L. Parker, J. J. Lugus, and K. Walsh, “Adipokines in inflammation and metabolic disease,” Nature Reviews Immunology, vol. 11, no. 2, pp. 85–97, 2011.

[76] P. S. Cooke and A. Naaz, “Role of estrogens in adipocyte development and function,” Experimental Biology and Medicine, vol. 229, no. 11, pp. 1127–1135, 2004.

[77] N. Geary, L. Asarian, K. S. Korach, D. W. Pfaff, and S. Ogawa, “Deficits in E2-dependent control of feeding, weight gain, and cholecystokinin satiation in ER-α null mice,” Endocrinology, vol. 142, no. 11, pp. 4751–4757, 2001.

[78] M. E. Jones, A. W. Thorburn, K. L. Britt et al., “Aromatase-deficient (arko) mice have a phenotype of increased adiposity,” Proceedings of the National Academy of Sciences of the United States of America, vol. 97, no. 23, pp. 12735–12740, 2000.

[79] M. Lafontan, “Fat cells: afferent and efferent messages define new approaches to treat obesity,” Annual Review of Pharmacology and Toxicology, vol. 45, pp. 119–146, 2005.

[80] F. Machinal, M.-N. Dieudonne, M.-C. Leneveu, R. Pecquerey, and Y. Giudicelli, “In vivo and in vitro ob gene expression and leptin secretion in rat adipocytes: evidence for a regional specific regulation by sex steroid hormones,” Endocrinology, vol. 140, no. 4, pp. 1567–1574, 1999.

[81] S. Kafkas, T. Dost, H. Ozkayran, C. Yenisey, P. Tuncyurek, and M. Birincioglu, “Effect of estrogen therapy on adipokines in ovariectomized-aged rats,” The Journal of Obstetrics and Gynaecology Research, vol. 38, no. 1, pp. 231–238, 2012.

[82] Y. Zhou and L. Rui, “Leptin signaling and leptin resistance,” Frontiers of Medicine, vol. 7, no. 2, pp. 207–222, 2013.

[83] G. Fantuzzi, “Three questions about leptin and immunity,” Brain, Behavior, and Immunity, vol. 23, no. 4, pp. 405–410, 2009.

[84] M. Materese, C. Procaccini, V. de Rosa, T. L. Horvath, and A. La Cava, “Regulatory T cells in obesity: the leptin connection,” Trends in Molecular Medicine, vol. 16, no. 6, pp. 247–256, 2010.

[85] E. D. Carlton, G. E. Demas, and S. S. French, “Leptin, a neuroendocrine mediator of immune responses, inflammation, and sickness behaviors,” Hormones and Behavior, vol. 62, no. 3, pp. 272–279, 2012.

[86] A. Joharapurkar, N. Dhanesha, G. Shah, R. Kharul, and M. Jain, “11β-Hydroxysteroid dehydrogenase type I: potential therapeutic target for metabolic syndrome,” Pharmacological Reports, vol. 64, no. 5, pp. 1055–1065, 2012.

[87] M. Alemayehu, “Do the interactions between glucocorticoids and sex hormones regulate the development of the metabolic syndrome?” Frontiers in Endocrinology, vol. 3, article 27, 2012.

[88] M. Alemayehu, “Steroid hormones interrelationships in the metabolic syndrome: an introduction to the ponderostat hypothesis,” Hormones, vol. 11, no. 3, pp. 272–289, 2012.
S. R. Salpéter, J. M. E. Walsh, T. M. Ormiston, E. Greyber, N. S. Buckley, and E. E. Salpéter, “Meta-analysis: effect of hormone-replacement therapy on components of the metabolic syndrome in postmenopausal women,” Diabetes, Obesity and Metabolism, vol. 8, no. 5, pp. 538–554, 2006.

R. H. Eckel, S. M. Grundy, and P. Z. Zimmet, “The metabolic syndrome,” The Lancet, vol. 365, no. 9468, pp. 1415–1428, 2005.

M. Lafontan and M. Berlan, “Do regional differences in adipocyte biology provide new pathophysiological insights?” Trends in Pharmacological Sciences, vol. 24, no. 6, pp. 276–283, 2003.

M. Laclaustra, D. Corella, and J. M. Ordovas, “Metabolic syndrome pathophysiology: the role of adipose tissue,” Nutrition, Metabolism and Cardiovascular Diseases, vol. 17, no. 2, pp. 125–139, 2007.

E. E. Kershaw and J. S. Flier, “Adipose tissue as an endocrine organ,” Journal of Clinical Endocrinology and Metabolism, vol. 89, no. 6, pp. 2548–2556, 2004.

H. E. Bays, J. M. Gonzalez-Campoy, G. A. Bray et al., “Pathogenic potential of adipose tissue and metabolic consequences of adipocyte hypertrophy and increased visceral adiposity,” Expert Review of Cardiovascular Therapy, vol. 6, no. 3, pp. 343–368, 2008.

V. van Harmelen, A. Dicker, M. Rydén et al., “Increased lipolysis and decreased leptin production by human omental as compared with subcutaneous preadipocytes,” Diabetes, vol. 51, no. 7, pp. 2029–2036, 2002.

B. L. Wajchenberg, “Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome,” Endocrine Reviews, vol. 21, no. 6, pp. 697–738, 2000.

M. Cnop, M. J. Landchild, J. Vidal et al., “The concurrent accumulation of intra-abdominal and subcutaneous fat explains the association between insulin resistance and plasma leptin concentrations: distinct metabolic effects of two fat compartments,” Diabetes, vol. 51, no. 4, pp. 1005–1015, 2002.

A. Katsuki, Y. Sumida, H. Urakawa et al., “Increased visceral fat and serum levels of triglyceride are associated with insulin resistance in Japanese metabolically obese, normal weight subjects with normal glucose tolerance,” Diabetes Care, vol. 26, no. 8, pp. 2341–2344, 2003.

L. E. Wagenknecht, C. D. Langefeld, A. L. Scherzinger et al., “Insulin sensitivity, insulin secretion, and abdominal fat: the insulin resistance atherosclerosis study (iras) family study,” Diabetes, vol. 52, no. 10, pp. 2490–2496, 2003.

T. Hayashi, E. J. Boyko, D. L. Leonetti et al., “Visceral adiposity and the risk of impaired glucose tolerance: a prospective study among Japanese Americans,” Diabetes Care, vol. 26, no. 3, pp. 650–655, 2003.

F. Bacha, R. Saad, N. Gungor, J. Janosky, and S. A. Arslanian, “Obesity, regional fat distribution, and syndrome X in obese black versus white adolescents: race differential in diabetogenic and atherogenic risk factors,” Journal of Clinical Endocrinology and Metabolism, vol. 88, no. 6, pp. 2534–2540, 2003.

C. Rattarasarn, R. L. Lawrence, S. Soonthornpun et al., “Regional abdominal fat distribution in lean and obese Thai type 2 diabetic women: relationships with insulin sensitivity and cardiovascular risk factors,” Metabolism: Clinical and Experimental, vol. 52, no. 11, pp. 1444–1447, 2003.

D. J. Nieves, M. Cnop, B. Retzlaff et al., “The atherogenic lipoprotein profile associated with obesity and insulin resistance is largely attributable to intra-abdominal fat,” Diabetes, vol. 52, no. 1, pp. 172–179, 2003.

E. Bertin, P. Nguyen, M. Guenounou, V. Durlach, G. Potron, and M. Leutenegger, “Plasma levels of tumor necrosis factor-alpha (TNF-α) are essentially dependent on visceral fat amount in type 2 diabetic patients,” Diabetes and Metabolism, vol. 26, no. 3, pp. 178–182, 2000.

M. C. Alessi, F. Peiretti, P. Morange, M. Henry, G. Nabhorne, and I. Juhan-Vague, “Production of plasminogen activator inhibitor 1 by human adipose tissue: possible link between visceral fat accumulation and vascular disease,” Diabetes, vol. 46, no. 5, pp. 860–867, 1997.

T. You, B. J. Nicklas, J. Ding et al., “The metabolic syndrome is associated with circulating adipokines in older adults across
a wide range of adiposity," *Journals of Gerontology Series A: Biological Sciences and Medical Sciences*, vol. 63, no. 4, pp. 414–419, 2008.

[118] M. Cnop, P. J. Havel, K. M. Utschneider et al., "Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: evidence for independent roles of age and sex," *Diabetologia*, vol. 46, no. 4, pp. 459–469, 2003.

[119] R. A. Hegele, T. R. Joy, S. A. Al-Attar, and B. K. Rutt, "Thematic review series: adipocyte biology. Lipodystrophies: Windows on adipose biology and metabolism," *Journal of Lipid Research*, vol. 48, no. 7, pp. 1433–1444, 2007.

[120] V. R. Agarwal, C. I. Ashanullah, E. R. Simpson, and S. E. Bulun, "Alternatively spliced transcripts of the aromatase cytochrome P450 (CYP19) gene in adipose tissue of women," *The Journal of Clinical Endocrinology and Metabolism*, vol. 82, no. 1, pp. 70–74, 1997.

[121] E. J. Folkerd, M. J. Reed, and V. H. James, "Oestrogen production in adipose tissue from normal women and women with endometrial cancer in vivo," *The Journal of Steroid Biochemistry*, vol. 16, no. 2, pp. 297–302, 1982.

[122] S. E. Bulun, Z. Lin, G.imir et al., "Regulation of aromatase expression in estrogen-responsive breast and uterine disease: from bench to treatment," *Pharmacological Reviews*, vol. 57, no. 3, pp. 359–383, 2005.

[123] C. Gignarella, M. Kratz, and C. Bolego, "Emerging role of estrogen in the control of cardiometabolic disease," *Trends in Pharmacological Sciences*, vol. 31, no. 4, pp. 183–189, 2010.

[124] S. A. Salama, M. W. Kamel, C. R. Diaz-Arrastia et al., "Effect of tumor necrosis factor-α on estrogen metabolism and endometrial cells: potential physiological and pathological relevance," *The Journal of Clinical Endocrinology & Metabolism*, vol. 94, no. 1, pp. 285–293, 2009.

[125] M. E. Simpson, M. Misso, K. N. Hewitt et al., "Estrogen—the good, the bad, and the unexpected," *Endocrine Reviews*, vol. 26, no. 3, pp. 322–330, 2005.

[126] T. M. D’Eon, S. C. Souza, M. Aronovitz, M. S. Obin, S. K. Fried, and A. S. Greenberg, "Estrogen regulation of adiposity and fuel partitioning: evidence of genomic and non-genomic regulation of lipogenic and oxidative pathways," *Journal of Biological Chemistry*, vol. 280, no. 43, pp. 35983–35991, 2005.

[127] J. Hong, R. E. Stubbins, R. R. Smith, A. E. Harvey, and N. P. Núñez, "Diffenential susceptibility to obesity between male and ovarioctomized female mice," *Nutrition Journal*, vol. 8, no. 1, article 11, 2009.

[128] I. F. Godsland, "Oestrogens and insulin secretion," *Diabetologia*, vol. 48, no. 11, pp. 2213–2220, 2005.

[129] E. Riant, A. Waget, H. Cogo, J.-F. Arnal, R. Burcelin, and P. Gourdy, "Estrogens protect against high-fat diet-induced insulin resistance and glucose intolerance in mice," *Endocrinology*, vol. 150, no. 5, pp. 2109–2117, 2009.

[130] S. E. Simpson, "Aromatase: biologic relevance of tissue-specific expression," *Seminars in Reproductive Medicine*, vol. 22, no. 1, pp. 11–23, 2004.

[131] M. E. E. Jones, A. W. Thorburn, K. L. Britt et al., "Aromatase-deficient (ArKO) mice accumulate excess adipose tissue," *The Journal of Steroid Biochemistry and Molecular Biology*, vol. 79, no. 1–5, pp. 3–9, 2001.

[132] Y. Nemoto, K. Toda, M. Ono et al., "Altered expression of fatty acid-metabolizing enzymes in aromatase-deficient mice," *Journal of Clinical Investigation*, vol. 105, no. 12, pp. 1819–1825, 2000.

[133] M. Nilsson, I. Dahlman, M. Rydén et al., "Oestrogen receptor α gene expression levels are reduced in obese compared to normal weight females," *International Journal of Obesity*, vol. 31, no. 6, pp. 900–907, 2007.

[134] T. Okura, M. Koda, F. Ando, N. Niino, S. Ohta, and H. Shimokata, "Association of polymorphisms in the estrogen receptor α gene with body fat distribution," *International Journal of Obesity*, vol. 27, no. 9, pp. 1020–1027, 2003.

[135] P. A. Heine, J. A. Taylor, G. A. Iwamoto, D. B. Lubahn, and P. S. Cooke, "Increased adipose tissue in male and female estrogen receptor-α knockout mice," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 97, no. 23, pp. 12729–12734, 2000.

[136] V. Ribas, M. T. A. Nguyen, D. C. Henstridge et al., "Impaired oxidative metabolism and inflammation are associated with insulin resistance in ERα-deficient mice," *American Journal of Physiology—Endocrinology and Metabolism*, vol. 298, no. 2, pp. E304–E319, 2010.

[137] C. Ohlsson, N. Hellberg, P. Parini et al., "Obesity and disturbed lipoprotein profile in estrogen receptor-alpha-deficient male mice," *Biochemical and Biophysical Research Communications*, vol. 278, pp. 640–645, 2000.

[138] K. E. Davis, M. D. Neinast, K. Sun et al., "The sexually dimorphic role of adipose and adipocyte estrogen receptors in modulating adipose tissue expansion, inflammation, and fibrosis," *Molecular Metabolism*, vol. 2, no. 3, pp. 227–242, 2013.

[139] H. Shi, S. P. Kumar, and X. Liu, "G protein-coupled estrogen receptor in energy homeostasis and obesity pathogenesis," *Progress in Molecular Biology and Translational Science*, vol. 114, pp. 193–250, 2013.

[140] C. Wang, B. Dehghani, I. J. Magrisso et al., "GPR30 contributes to estrogen-induced thymic atrophy," *Molecular Endocrinology*, vol. 22, no. 3, pp. 636–648, 2008.

[141] G. Sharma, C. Hu, J. L. Brigan, G. Zhu, H. J. Hathaway, and E. R. Prossnitz, "GPER deficiency in male mice results in insulin resistance, dyslipidemia, and a proinflammatory state," *Endocrinology*, vol. 154, no. 11, pp. 4136–4145, 2013.

[142] U. E. A. Martensson, S. A. Salehi, S. Windahl et al., "Deletion of the G protein-coupled receptor 30 impairs glucose tolerance, reduces bone growth, increases blood pressure, and eliminates estradiol-stimulated insulin release in female mice," *Endocrinology*, vol. 150, no. 2, pp. 687–698, 2009.

[143] S. Liu, C. Le May, W. P. S. Wong et al., "Importance of extranuclear estrogen receptors and membrane G protein-coupled estrogen receptor in pancreatic islet survival," *Diabetes*, vol. 58, no. 10, pp. 2292–2302, 2009.

[144] E.-J. Hong, M.-P. Levasseur, C. R. Dufour, M.-C. Perry, and V. Giguère, "Loss of estrogen-related receptor—promotes hepatocarcinogenesis development via metabolic and inflammatory disturbances," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 110, no. 44, pp. 17975–17980, 2013.

[145] M. S. Kim, J. K. Shigenaga, A. H. Moser, K. R. Feingold, and C. Grunfeld, "Suppression of estrogen-related receptor α and medium-chain acyl-coenzyme A dehydrogenase in the acute-phase response," *The Journal of Lipid Research*, vol. 46, no. 10, pp. 2282–2288, 2005.

[146] J. Misra, D. Chanda, D.-K. Kim et al., "Orphan nuclear receptor err induces C-reactive protein gene expression through induction of ER-bound bzip transmembrane transcription factor CREBH," *PLoS ONE*, vol. 9, no. 1, Article ID e86342, 2014.
[147] J. Gao, J. He, X. Shi et al., "Sex-specific effect of estrogen sulfotransferase on mouse models of type 2 diabetes," *Diabetes*, vol. 61, no. 6, pp. 1543–1551, 2012.

[148] R. S. Ahima, T. L. Stanley, V. K. Khor, M. V. Zanni, and S. K. Grinspan, "Estrogen sulfotransferase is expressed in subcutaneous adipose tissue of obese humans in association with TNF-α and SOCS3," *The Journal of Clinical Endocrinology & Metabolism*, vol. 96, no. 7, pp. E1153–E1158, 2011.

[149] Y. Xu, X. Yang, Z. Wang et al., "Estrogen sulfotransferase (SULT1E1) regulates inflammatory response and lipid metabolism of human endothelial cells via PPARγ," *Molecular and Cellular Endocrinology*, vol. 369, no. 1-2, pp. 140–149, 2013.

[150] M. Jiang, J. He, H. Kucera et al., "Hepatic over-expression of steroid sulfatase ameliorates mouse models of obesity and type 2 diabetes through sex-specific mechanisms," *The Journal of Biological Chemistry*, vol. 289, no. 12, pp. 8086–8097, 2014.

[151] I. C. Villar, A. J. Hobbs, and A. Ahluwalia, "Sex differences in vascular function: implication of endothelium-derived hyper-polarizing factor," *Journal of Endocrinology*, vol. 197, no. 3, pp. 447–462, 2008.

[152] G. L. Anderson, M. Limacher, A. R. Assaf et al., "Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the women's health initiative randomized controlled trial," *The Journal of the American Medical Association*, vol. 291, pp. 1701–1712, 2004.

[153] J. E. Manson, S. S. Bassuk, S. M. Harman et al., "Postmenopausal hormone therapy: new questions and the case for new clinical trials," *Menopause*, vol. 13, no. 1, pp. 139–147, 2006.

[154] L. Lundholm, H. Zang, A. L. Hirschberg, J.-Å. Gustafsson, P. Arner, and K. Dahlman-Wright, "Key lipogenic gene expression can be decreased by estrogen in human adipose tissue," *Fertility and Sterility*, vol. 90, no. 1, pp. 44–48, 2008.

[155] T. M. Price, S. N. O’Brien, B. H. Welter, R. George, J. Anandjiwala, and M. Kilgore, "Estrogen regulation of adipose tissue lipoprotein lipase—possible mechanism of body fat distribution," *American Journal of Obstetrics and Gynecology*, vol. 178, no. 1, pp. 101–107, 1998.

[156] A. Alonso, H. González-Pardo, P. Garrido et al., "Acute effects of 17β-estradiol and genistein on insulin sensitivity and spatial memory in aged ovariecetomized female rats," *Age*, vol. 32, no. 4, pp. 421–434, 2010.

[157] R. E. Van Pelt, W. S. Gozansky, R. S. Schwartz, and W. M. Kohrt, "Intravenous estrogens increase insulin clearance and action in postmenopausal women," *American Journal of Physiology: Endocrinology and Metabolism*, vol. 285, no. 2, pp. E311–E317, 2003.

[158] E. B. Geer and W. Shen, "Gender differences in insulin resistance, body composition, and energy balance," *Gender Medicine*, vol. 6, no. 1, pp. 60–75, 2009.

[159] K. Kon Koh, J. Y. Ahn, M. H. Kang et al., "Effects of hormone replacement therapy on plaque stability, inflammation, and fibrinolysis in hypertensive or overweight postmenopausal women," *The American Journal of Cardiology*, vol. 88, no. 12, pp. 1423–1426, 2001.

[160] A. Silvestri, O. Gheara, C. Vitale et al., "Increased levels of C-reactive protein after oral hormone replacement therapy may not be related to an increased inflammatory response," *Circulation*, vol. 107, no. 25, pp. 3165–3169, 2003.

[161] L. B. Tankó and C. Christiansen, "Adipose tissue, insulin resistance and low-grade inflammation: implications for atherogenesis and the cardiovascular harm of estrogen plus progestogen therapy," *Climacteric*, vol. 9, no. 3, pp. 169–180, 2006.

[162] M. C. Chu, M. Cushman, R. Solomon, and R. A. Lobo, "Metabolic syndrome in postmenopausal women: the influence of oral or transdermal estradiol on inflammation and coagulation markers," *American Journal of Obstetrics & Gynecology*, vol. 199, no. 5, pp. 526.e1–526.e7, 2008.

[163] G. A. Bray, "Risks of obesity," *Endocrinology and Metabolism Clinics of North America*, vol. 32, no. 4, pp. 787–804, 2003.

[164] J. Smith, M. Al-Amri, P. Dorairaj, and A. Sniderman, "The adipocyte life cycle hypothesis," *Clinical Science*, vol. 110, no. 1, pp. 1–9, 2006.

[165] G. Medina-Gómez and A. Vidal-Puig, "Adipose tissue as a therapeutic target in obesity," *Endocrinología y Nutrición*, vol. 56, no. 8, pp. 404–411, 2009.

[166] B. Gustafson, S. Gogg, S. Hedjazifar, L. Jenndahl, A. Hammarstedt, and U. Smith, "Inflammation and impaired adipogenesis in hypertrophic obesity in men," *The American Journal of Physiology—Endocrinology and Metabolism*, vol. 297, no. 5, pp. E999–E1003, 2009.

[167] P. Isaksson, A. Hammarstedt, B. Gustafson, and U. Smith, "Impaired preadipocyte differentiation in human abdominal obesity: role of Wnt, tumor necrosis factor-α, and inflammation," *Diabetes*, vol. 58, no. 7, pp. 1550–1557, 2009.

[168] J. K. Sethi and A. J. Vidal-Puig, "Thematic review series: adipocyte Biology. Adipose tissue function and plasticity orchestrated nutritional adaptation," *The Journal of Lipid Research*, vol. 48, no. 6, pp. 1253–1262, 2007.

[169] M. F. Gregor and G. S. Hotamisligil, "Adipocyte stress: the endoplasmatic reticulum and metabolic disease," *The Journal of Lipid Research*, vol. 48, no. 9, pp. 1905–1914, 2007.

[170] S. Cinti, G. Mitchell, G. Barbatelli et al., "Adipocyte death defines macrophage localization and function in adipose tissue of obese mice and humans," *Journal of Lipid Research*, vol. 46, no. 11, pp. 2347–2355, 2005.

[171] K. J. Strissel, Z. Stancheva, H. Miyoshi et al., "Adipocyte death, adipose tissue remodeling, and obesity complications," *Diabetes*, vol. 56, no. 12, pp. 2910–2918, 2007.

[172] S. de Ferranti and D. Mozaffarian, "The perfect storm: obesity, metabolic syndrome in adults?" *Clinical Chemistry*, vol. 54, no. 6, pp. 945–955, 2008.

[173] M. Jern˚as, J. Palming, K. Sj¨oholm et al., "Separation of human adipose tissue from various body sites of surgery-induced weightloss," *Journal of Endocrinological Investigation*, vol. 30, no. 3, pp. 210–214, 2007.

[174] S. A. Arikan, "The correlation between adiposity and adiponectin, tumor necrosis factor α, interleukin-6 and high sensitivity C-reactive protein levels. Is adipocyte size associated with inflammation in adults?" *Journal of Endocrinology & Metabolism*, vol. 32, no. 4, pp. 787–804, 2003.

[175] M. Bahceci, D. Gokalp, S. Bahceci, A. Tuzcu, S. Atmaca, and S. Arikan, "The correlation between adiposity and adiponection, tumor necrosis factor α, interleukin-6 and high sensitivity C-reactive protein levels. Is adipocyte size associated with inflammation in adults?" *Journal of Endocrinology & Metabolism*, vol. 32, no. 4, pp. 787–804, 2003.
Mediators of Inflammation

[178] S. L. Palin, P. G. McTernan, L. A. Anderson, D. W. Sturdee, A. H. Barnett, and S. Kumar, “17β-Estradiol and anti-estrogen ICI:compound 182,780 regulate expression of lipoprotein lipase and hormone-sensitive lipase in isolated subcutaneous abdominal adipocytes,” Metabolism: Clinical and Experimental, vol. 52, no. 4, pp. 383–388, 2003.

[179] G. E. Ackerman, P. C. MacDonald, G. Gudelsky, C. R. Mendelson, and E. R. Simpson, “Potentiation of epinephrine-induced lipolysis by catechol estrogens and their methoxy derivatives,” Endocrinology, vol. 109, no. 6, pp. 2084–2088, 1981.

[180] M. L. Misso, Y. Murata, W. C. Boon, M. E. E. Jones, K. L. Britt, and E. R. Simpson, “Cellular and molecular characterization of the adipose phenotype of the aromatase-deficient mouse,” Endocrinology, vol. 144, no. 4, pp. 1474–1480, 2003.

[181] G. Bryzgalova, L. Lundholm, N. Portwood et al., “Mechanisms of antiadibetogenic and body weight-lowering effects of estrogen in high-fat diet-fed mice,” American Journal of Physiology—Endocrinology and Metabolism, vol. 295, no. 4, pp. E904–E912, 2008.

[182] E. G. dos Santos, M. N. Dieudonné, R. Peccuary, V. le Moal, Y. Giudicelli, and D. Lacasa, “Rapid nongenomic E2 effects on p42/p44 MAPK, activator protein-1, and CAMP response element binding protein in rat white adipocytes,” Endocrinology, vol. 143, no. 3, pp. 930–940, 2002.

[183] L. Sjöström, U. Smith, M. Krotkiewski, and P. Björntorp, “Cellularity in different regions of adipose tissue in young men and women,” Metabolism, vol. 21, no. 12, pp. 1143–1153, 1972.

[184] M. N. Dieudonné, M. C. Leneveu, Y. Giudicelli, and R. Peccuary, “Evidence for functional estrogen receptors α and β in human adipose cells: regional specificities and regulation by estrogens,” American Journal of Physiology: Cell Physiology, vol. 286, no. 3, pp. C655–C661, 2004.

[185] L. A. Anderson, P. G. McTernan, A. H. Barnett, and S. Kumar, “The effects of androgens and estrogens on preadipocyte proliferation in human adipose tissue: influence of gender and site,” Journal of Clinical Endocrinology and Metabolism, vol. 86, no. 10, pp. 5045–5051, 2001.

[186] P. A. Heine, D. B. Lubahn, D. H. Keisler, M. Hufford, and P. S. Cooke, “Role of estrogen receptor alpha (er alpha) in white adipose tissue (wat) deposition in mice,” Biology of Reproduction, vol. 62, pp. 306–307, 2000.

[187] R. E. Stubbins, V. B. Holcomb, J. Hong, and N. P. Núñez, “Estrogen modulates abdominal adiposity and protects female mice from obesity and impaired glucose tolerance,” European Journal of Nutrition, vol. 51, no. 7, pp. 861–870, 2012.

[188] S. P. Weisberg, D. McCann, M. Desai, M. Rosenbaum, R. L. Leibel, and A. W. Ferrante Jr., “Obesity is associated with macrophage accumulation in adipose tissue,” Journal of Clinical Investigation, vol. 112, no. 12, pp. 1796–1808, 2003.

[189] S. Gordon, “Alternative activation of macrophages,” Nature Reviews Immunology, vol. 3, no. 1, pp. 23–35, 2003.

[190] R. Cancell, J. Tordjman, C. Poitou et al., “Increased infiltration of macrophages in omental adipose tissue is associated with marked hepatic lesions in morbid human obesity,” Diabetes, vol. 55, no. 6, pp. 1554–1561, 2006.

[191] A. Mantovani, A. Sica, S. Sozzani, P. Allavena, A. Vecchi, and M. Locati, “The chemokine system in diverse forms of macrophage activation and polarization,” Trends in Immunology, vol. 25, no. 12, pp. 677–686, 2004.

[192] E. Vegeto, C. Bonincontro, G. Pollio et al., “Estrogen prevents the lipopolysaccharide-induced inflammatory response in microglia,” The Journal of Neuroscience, vol. 21, no. 6, pp. 1809–1818, 2001.

[193] K. L. Phiel, R. A. Henderson, S. J. Adelman, and M. M. Elloso, “Differential estrogen receptor gene expression in human peripheral blood mononuclear cell populations,” Immunology Letters, vol. 97, no. 1, pp. 107–113, 2005.

[194] D. Rachon, J. Mysliwska, K. Suchecka-Rachon, J. Wieckiewicz, and A. Mysliwski, “Effects of oestrogen deprivation on interleukin-6 production by peripheral blood mononuclear cells of postmenopausal women,” Journal of Endocrinology, vol. 172, no. 2, pp. 387–395, 2002.

[195] K. Asai, N. Hiki, Y. Mimura, T. Ogawa, K. Unou, and M. Kaminishi, “Gender differences in cytokine secretion by human peripheral blood mononuclear cells: role of estrogen in modulating LPS-induced cytokine secretion in an ex vivo septic model,” Shock, vol. 16, no. 5, pp. 340–343, 2001.

[196] A. Rogers and R. Eastell, “The effect of 17β-estradiol on production of cytokines in cultures of peripheral blood,” Bone, vol. 29, no. 1, pp. 30–34, 2001.

[197] T. Suzuki, T. Shimizu, H.-P. Yu et al., “Tissue compartment-specific role of estrogen receptor subtypes in immune cell cytokine production following trauma-hemorrhage,” Journal of Applied Physiology, vol. 102, no. 1, pp. 163–168, 2007.

[198] K. C. Lambert, E. M. Curran, B. M. Judy, D. B. Lubahn, and D. M. Estes, “Estrogen receptor-α deficiency promotes increased TNF-α secretion and killing by murine macrophages in response to microbial stimuli in vitro,” Journal of Leukocyte Biology, vol. 75, no. 6, pp. 1166–1172, 2004.

[199] K. C. Lambert, E. M. Curran, B. M. Judy, G. N. Milligan, D. B. Lubahn, and D. M. Estes, “Estrogen receptor α (ERα) deficiency in macrophages results in increased stimulation of CD4+ T cells while 17β-estradiol acts through ERα to increase IL-4 and GATA-3 expression in CD4+ T cells independent of antigen presentation,” The Journal of Immunology, vol. 175, no. 9, pp. 5716–5723, 2005.

[200] V. Ribas, B. G. Drew, J. A. le et al., “Myeloid-specific estrogen receptor α deficiency impairs metabolic homeostasis and accelerates atherosclerotic lesion development,” Proceedings of the National Academy of Sciences of the United States of America, vol. 108, no. 39, pp. 16457–16462, 2011.

[201] E. Blasko, C. A. Haskell, S. Leung et al., “Beneficial role of the GPR30 agonist G-1 in a animal model of multiple sclerosis,” Journal of Neuroimmunology, vol. 214, no. 1-2, pp. 67–77, 2009.

[202] C. N. Lumeng, S. M. DeYoung, J. L. Bodzin, and A. R. Saltiel, “Increased inflammatory properties of adipose tissue macrophages recruited during diet-induced obesity,” Diabetes, vol. 56, no. 1, pp. 16–23, 2007.

[203] C. N. Lumeng, J. B. Delproposto, D. J. Westcott, and A. R. Saltiel, “Phenotypic switching of adipose tissue macrophages with obesity is generated by spatiotemporal differences in macrophage subtypes,” Diabetes, vol. 57, no. 12, pp. 3239–3246, 2008.

[204] C. Murdoch, M. Muthana, and C. E. Lewis, “Hypoxia regulates macrophage functions in inflammation,” The Journal of Immunology, vol. 175, no. 10, pp. 6257–6263, 2005.

[205] P. L. Harkonen and H. K. Vaananen, “Monocyte-macrophage system as a target for estrogen and selective estrogen receptor modulators,” Annals of the New York Academy of Sciences, vol. 1089, pp. 218–227, 2006.
[206] P. A. Pioli, A. L. Jensen, I. K. Weaver et al., “Estradiol attenuates lipopolysaccharide-induced CXC chemokine ligand 8 production by human peripheral blood monocytes,” *The Journal of Immunology*, vol. 179, no. 9, pp. 6284–6290, 2007.

[207] R. Deshpande, H. Khalili, R. G. Pergolizzi, S. D. Michael, and M.-D. Y. Chang, “Estradiol down-regulates LPS-induced cytokine production and NFkB activation in murine macrophages,” *The American Journal of Reproductive Immunology*, vol. 38, no. 1, pp. 46–54, 1997.

[208] M. R. Frazier-Jessen and E. J. Kovacs, “Estrogen modulation of JE/monocyte chemoattractant protein-1 mRNA expression in murine macrophages,” *The Journal of Immunology*, vol. 154, no. 4, pp. 1838–1845, 1995.

[209] A. J. Murphy, P. M. Guyre, and P. A. Pioli, “Estradiol suppresses NF-kB activation through coordinated regulation of let-7a and miR-125b in primary human macrophages,” *The Journal of Immunology*, vol. 184, no. 9, pp. 5029–5037, 2010.

[210] M. A. Elobeid and D. B. Allison, “Putative environmental-endocrine disruptors and obesity: a review,” *Current Opinion in Endocrinology, Diabetes and Obesity*, vol. 15, no. 5, pp. 403–408, 2008.

[211] R. R. Newbold, “Impact of environmental endocrine disrupting chemicals on the development of obesity,” *Hormones*, vol. 9, no. 3, pp. 206–217, 2010.

[212] E. Swedenborg, J. Ruegg, S. Mikela, and I. Pongratz, “Endocrine disruptive chemicals: mechanisms of action and involvement in metabolic disorders,” *Journal of Molecular Endocrinology*, vol. 43, no. 1, pp. 1–10, 2009.

[213] D. Teixeira, D. Pestana, C. Calhau, and R. Monteiro, “Estrogens as mediators of obesity-induced inflammation,” in *Estrogens: Biochemistry, Therapeutic Uses and Physiological Effects*, V. J. Thompson and A. E. Watson, Eds., pp. 1–46, Nova Science, New York, NY, USA, 2012.

[214] S. C. Low, S. N. Assaad, V. Rajan, K. E. Chapman, C. R. Edwards, and J. R. Seckl, “Regulation of 11β-hydroxysteroid dehydrogenase by sex steroids in vivo: Further evidence for the existence of a second dehydrogenase in rat kidney,” *The Journal of Endocrinology*, vol. 139, no. 1, pp. 27–35, 1993.

[215] S. K. Paulsen, M. P. Nielsen, B. Richelsen, J. M. Bruun, A. Flyvbjerg, and S. B. Pedersen, “Upregulation of adipose 11-B-hydroxysteroid dehydrogenase type 1 expression in ovariectomized rats is due to obesity rather than lack of estrogen,” *Obesity*, vol. 16, no. 4, pp. 731–735, 2008.